initials_extractor,initials_checker,status,comment,ma_aut_year,ma_id,ma_e_id,source,figure_save,info_population,chemical_class,chemical_s,chemical_id,health_outcome,proxy_biomarker,health_outcome_type,ICD11_code,health_outcome_class,health_outcome_group,health_outcome_comment,n_ps,n_ps_e,model,model_comment,variance_estimate_method,ma_es_measure,regression_type,regression_type_comment,ma_point_estimate,ma_l_ci,ma_u_ci,ma_se,ma_sd,I_squared,tau_squared,heterogeneity (Cochrane Q-statistic)
KM,,completed,NA,ingber_2013,ma_001,ma_m_001,fig2a,ingber_2013_fig2a,,OCP,one,DDE,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,,random effects model,,not reported,OR (odds ratio),,,0.901,0.749,1.084,NA,NA,,,
KM,,completed,NA,ingber_2013,ma_001,ma_m_002,fig2b,ingber_2013_fig2b,,OCP,one,DDE,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,,random effects model,,not reported,OR (odds ratio),,,1.107,0.978,1.252,NA,NA,,,
KM,,completed,NA,park_2016,ma_002,ma_m_003,fig2,park_2016_fig2,,OCP,one,"p,p'-DDE",yes,,hypertension,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,,random effects model,,not reported,OR (odds ratio),,,1.1,1.03,1.18,NA,NA,0,,
KM,,completed,NA,canosancho_2017,ma_003,ma_m_004,fig3,canosancho_2017_fig3,,OCP,one,"p,p'-DDE",yes,,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,,,random effects model,,not reported,adjusted coefficient regression (?),,,0.13,0.01,0.25,NA,NA,39.5,,
KM,,completed,NA,fu_2020,ma_004,ma_m_005,fig4,fu_2020_fig4_DDE,,OCP,one,"p,p'-DDE",yes,,cardiovascular disease,,cardiovascular diseases,,,,,random effects model,,not reported,OR (odds ratio),,,1.2,1.08,1.34,NA,NA,53.5,,
KM,,completed,NA,fu_2020,ma_004,ma_m_006,fig4,fu_2020_fig4_HCB,,OCP,one,HCB,yes,,cardiovascular disease,,cardiovascular diseases,,,,,random effects model,,not reported,OR (odds ratio),,,1.06,0.89,1.27,NA,NA,45.1,,
KM,,completed,NA,fu_2020,ma_004,ma_m_007,fig4,fu_2020_fig4_HCH,,OCP,one,beta-HCH,yes,,cardiovascular disease,,cardiovascular diseases,,,,,random effects model,,not reported,OR (odds ratio),,,1,0.69,1.46,NA,NA,87.5,,
KM,,completed,NA,hernandezmariano_2020,ma_005,ma_m_008,fig3a,hernandezmariano_2020_fig3a,,OCP,one,"p,p'-DDE",yes,,type 2 diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,,,random effects model,,not reported,OR (odds ratio),,,1.44,1,2.07,NA,NA,44.4,,
KM,,completed,NA,hernandezmariano_2020,ma_005,ma_m_009,fig5,hernandezmariano_2020_fig5,,OCP,one,"p,p'-DDE",yes,,hypertension,BA00.Z,"Essential hypertension, unspecified",Diseases of the circulatory system,,,,random effects model,,not reported,OR (odds ratio),,,1.21,1.07,1.38,NA,NA,9.3,,
KM,,completed,"states risk ratio or odds ratio, no overall metrics provided for the analysis but provdes a combined analysis for just DDT and DDE seperaretely ",odutola_2021,ma_006,ma_m_010,,,,,,,,,,,,,,,,random effects model,,not reported,OR (odds ratio),,,not reported,not reported,not reported,not reported,not reported,not reported,,
KM,,completed,NA,tang_2014,ma_007,ma_m_011,fig2c,tang_2014_fig2c,,OCP,one,"p,p'-DDE",yes,,type 2 diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.33,1.15,1.54,NA,NA,25,,
KM,,completed,NA,sun_2022,ma_008,ma_m_012,fig2,sun_2022_fig2,,OCP,multiple,combined ocp,yes,,thyroid function,KB62.Y,Other specified transitory neonatal disorders of thyroid function,"Endocrine, nutritional or metabolic diseases",in neonates,,,random effects model,,DerSimonian and Laird,adjusted coefficient regression (?),,,0,-0.02,0.02,NA,NA,0,,
KM,,completed,NA,stratakis_2021,ma_009,ma_m_013,fig2a,stratakis_2021_fig2a,,OCP,one,DDE,yes,,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,,,random effects model,,not reported,adjusted coefficient regression (?),,,0.12,0.03,0.21,NA,NA,28.15,,
KM,,completed,NA,stratakis_2021,ma_009,ma_m_014,fig2c,stratakis_2021_fig2b,,OCP,one,HCB,yes,,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,,,random effects model,,not reported,adjusted coefficient regression (?),,,0.31,0.09,0.53,NA,NA,31.88,,
KM,,completed,NA,stratakis_2021,ma_009,ma_m_015,fig3a,stratakis_2021_fig3a,children (2–11?years),PFAS,one,PFOS,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,10,random effects model,,not reported,adjusted coefficient regression (?),logistic,"""We used multivariable logistic regression to estimate adjusted odds ratios (ORs)"". From Lauritzen HB, Larose TL, Oien T, et al. Prenatal exposure to persistent organic pollutants and child overweight/obesity at 5-year follow-up: a prospective cohort study. Environ Health. 2018;17(1):9.",0,-0.01,0.01,NA,NA,42.86,NA,NA
KM,,completed,NA,stratakis_2021,ma_009,ma_m_016,fig3b,stratakis_2021_fig3b,children (2–11?years),PFAS,one,PFOA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,10,random effects model,,not reported,adjusted coefficient regression (?),logistic,"""We used multivariable logistic regression to estimate adjusted odds ratios (ORs)"". From Lauritzen HB, Larose TL, Oien T, et al. Prenatal exposure to persistent organic pollutants and child overweight/obesity at 5-year follow-up: a prospective cohort study. Environ Health. 2018;17(1):9.",0.03,-0.02,0.08,NA,NA,55.52,NA,NA
KM,,completed,NA,luo_2016,ma_010,ma_m_017,fig2,luo_2016_fig2_DDT,,OCP,one,DDT,yes,,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.02,0.81,1.28,NA,NA,0,,
KM,,completed,NA,luo_2016,ma_010,ma_m_018,fig2,luo_2016_fig2_DDE,,OCP,one,DDE,yes,,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.38,1.14,1.66,NA,NA,0,,
KM,,completed,NA,luo_2016,ma_010,ma_m_019,fig2,luo_2016_fig2_HCH,,OCP,one,HCH,yes,,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.42,1.08,1.87,NA,NA,34.4,,
KM,,completed,NA,luo_2016,ma_010,ma_m_020,fig2,luo_2016_fig2_chlordane,,OCP,one,Chlordane,yes,,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.93,1.51,2.48,NA,NA,17.7,,
KM,,completed,NA,luo_2016,ma_010,ma_m_021,fig2,luo_2016_fig2_HCB,,OCP,one,HCB,yes,,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.54,1.2,1.99,NA,NA,17.7,,
KM,,completed,NA,park_2014,ma_011,ma_m_022,fig2,park_2014_fig2,,OCP,one,DDE,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,,random effects model,,not reported,OR (odds ratio),,,1.03,0.95,1.12,NA,NA,40.9,,
KM,,completed,NA,mosallanejad_2016,ma_012,ma_m_023,fig2,mosallanejad_2016_fig2,,OCP,one,HCB,yes,,type 2 diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,not reported,OR (odds ratio),,,2.23,1.82,2.74,NA,NA,25.95,,
KM,,completed,no overall reported,brown_2006,ma_013,ma_m_024,fig2,brown_2006_fig2,,OCP,multiple,combined ocp,yes,,parkinsons disease,8A00.0,Parkinson disease,Diseases of the nervous system,,,,not reported ,,not reported ,OR (odds ratio),,,not reported,not reported,not reported,not reported,not reported,not reported,,
KM,,completed,NA,wu_2022,ma_014,ma_m_025,fig3,wu_2022_fig3_DDE,,OCP,one,DDE,yes,,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,,,,random effects model,,not reported,OR (odds ratio),,,1.62,0.94,2.82,NA,NA,64.4,,
KM,,completed,NA,wu_2022,ma_014,ma_m_026,fig5,wu_2022_fig5_PFOS,children,PFAS,one,PFOS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,11,random effects model,,not reported,OR (odds ratio),NA,NA,1.26,0.84,1.91,NA,NA,75.6,NA,NA
KM,,completed,NA,wu_2022,ma_014,ma_m_027,fig5,wu_2022_fig5_PFUA,children,PFAS,one,PFUnDA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,3,random effects model,,not reported,OR (odds ratio),NA,NA,0.86,0.7,1.06,NA,NA,0,NA,NA
KM,,completed,NA,wu_2022,ma_014,ma_m_028,fig5,wu_2022_fig5_PFOA,children,PFAS,one,PFOA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,10,random effects model,,not reported,OR (odds ratio),NA,NA,1.06,0.8,1.4,NA,NA,46.3,NA,NA
KM,,completed,NA,wu_2022,ma_014,ma_m_029,fig5,wu_2022_fig5_PFNA,children,PFAS,one,PFNA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,6,random effects model,,not reported,OR (odds ratio),NA,NA,1.06,0.82,1.37,NA,NA,52,NA,NA
KM,,completed,NA,wu_2022,ma_014,ma_m_030,fig5,wu_2022_fig5_PFHxS,children,PFAS,one,PFHxS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,6,random effects model,,not reported,OR (odds ratio),NA,NA,1.01,0.82,1.23,NA,NA,0,NA,NA
KM,,completed,NA,wu_2022,ma_014,ma_m_031,fig5,wu_2022_fig5_PFDA,children,PFAS,one,PFDA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,3,random effects model,,not reported,OR (odds ratio),NA,NA,1.16,0.72,1.88,NA,NA,45,NA,NA
KM,,completed,NA,yipei_2022,ma_015,ma_m_032,fig2,yipei_2022_fig2,,OCP,one,DDT,yes,,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,,,random effects model,,not reported,OR (odds ratio),,,1.61,1.1,2.36,NA,NA,75,,
KM,,completed,NA,yipei_2022,ma_015,ma_m_033,fig3,yipei_2022_fig3,,OCP,one,DDE,yes,,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,,,random effects model,,not reported,OR (odds ratio),,,1.67,1.41,1.98,NA,NA,73,,
KM,,completed,study does an adjustment for 1ug/g of tissue - we can take these effect sizes also potentially,chittrakul_2021,ma_016,ma_m_034,fig4,chittrakul_2021_fig4,,OCP,multiple,combined ocp,yes,,asthma,CA23.3,Unspecified asthma,Diseases of the respiratory system ,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.4,1.19,1.64,NA,NA,37.3,,
KM,,completed,NA,lim_2015,ma_017,ma_m_035,fig2,lim_2015_fig2_DDE,,OCP,one,"p,p'-DDE",yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.41,1.12,1.78,NA,NA,24.8,,
KM,,completed,NA,lim_2015,ma_017,ma_m_036,fig2,lim_2015_fig2_trans-nonachlor,,OCP,one,trans-Nonachlordane,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.3,0.92,1.82,NA,NA,50.3,,
KM,,completed,NA,lim_2015,ma_017,ma_m_037,fig2,lim_2015_fig2_Oxychlordane,,OCP,one,Oxychlordane,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.18,0.82,1.69,NA,NA,0,,
KM,,completed,this study has a single chemical forest plot with mixed outcomes - then mixed chemical forest plots with single outcomes,bonde_2016,ma_018,ma_m_038,fig3,bonde_2016_fig3,,OCP,one,DDE,yes,,"cryptorchidism, hypospadias or testicular cancer",2C82,,Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.35,1.04,1.74,NA,NA,,,
KM,,completed,NA,bonde_2016,ma_018,ma_m_039,fig4,bonde_2016_fig4,,other,multiple,mixed edcs,yes,,cryptorchidism,2C82,,,,,,random effects model,,not reported,OR (odds ratio),,,1.03,0.72,1.47,NA,NA,,,
KM,,completed,NA,bonde_2016,ma_018,ma_m_040,fig5,bonde_2016_fig5,,other,multiple,mixed edcs,yes,,hypospadias,2C82,,,,,,random effects model,,not reported,OR (odds ratio),,,1.13,0.86,1.5,NA,NA,,,
KM,,completed,NA,bonde_2016,ma_018,ma_m_041,fig5,bonde_2016_fig6,,other,multiple,mixed edcs,yes,,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,,,,random effects model,,not reported,OR (odds ratio),,,1.2,0.78,1.89,NA,NA,,,
KM,,completed,NA,mendes_2021,ma_019,ma_m_042,fig2,mendes_2021_fig2,,OCP,one,Oxychlordane,yes,,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,DerSimonian and Laird,adjusted coefficient regression (?),,,0.04,0,0.07,NA,NA,89.7,,
KM,,completed,NA,mendes_2021,ma_019,ma_m_043,fig3,mendes_2021_fig3,,OCP,one,trans-Nonachlor,yes,,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,DerSimonian and Laird,adjusted coefficient regression (?),,,0.02,-0.01,0.06,NA,NA,78.7,,
KM,,completed,NA,mendes_2021,ma_019,ma_m_044,fig4,mendes_2021_fig4,,OCP,one,Oxychlordane,yes,,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,DerSimonian and Laird,adjusted coefficient regression (?),,,1.96,1.19,3.23,NA,NA,69.8,,
KM,,completed,NA,mendes_2021,ma_019,ma_m_045,fig5,mendes_2021_fig5,,OCP,one,trans-Nonachlor,yes,,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,DerSimonian and Laird,adjusted coefficient regression (?),,,2.43,1.64,3.62,NA,NA,63.2,,
KM,,completed,NA,mendes_2021,ma_019,ma_m_046,fig6,mendes_2021_fig6,,OCP,one,heptachlor epoxide,yes,,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,DerSimonian and Laird,adjusted coefficient regression (?),,,1.88,1.42,2.49,NA,NA,0,,
KM,,completed,states will use a model based on heterogeneity - seems to used fixed,he_2022,ma_020,ma_m_047,fig3,,,other,multiple,edcs,no,,rodent reproduction,2C82,,,,,,fixed effects model,,not reported,RR (risk ratio),,,2.45,1.92,3.12,NA,NA,11.5,,
KM,,completed,NA,wang_2021,ma_021,ma_m_048,tab2,,,OCP,multiple,combined ocp,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",,,,random effects model,,not reported,OR (odds ratio),,,1.14,0.8,1.65,NA,NA,51.2,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_049,fig2,lewis_mikhael_2015_fig2_DDE,,OCP,one,"p,p'-DDE",yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.02,0.69,1.35,NA,NA,12.7,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_050,fig2,lewis_mikhael_2015_fig2_DDT,,OCP,one,DDT,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,0.81,0.35,1.26,NA,NA,0,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_051,fig2,lewis_mikhael_2015_fig2_HCB,,OCP,one,HCB,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,0.88,0.18,1.57,NA,NA,36,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_052,fig2,lewis_mikhael_2015_fig2_oxychlordane,,OCP,one,Oxychlordane,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,0.91,0.46,1.35,NA,NA,0,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_053,fig2,lewis_mikhael_2015_fig2_transnonachlor,,OCP,one,trans-Nonachlor,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,0.88,0.45,1.31,NA,NA,0,,
KM,,completed,CHECK AS THIS IS DIFFERENT TO THE OTHER DDT IN THE STUDY ,lewis-mikhael_2015,ma_022,ma_m_054,fig3,lewis_mikhael_2015_fig3_DDT,,OCP,one,DDT,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.3,0.94,1.67,NA,NA,13.4,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_055,fig3,lewis_mikhael_2015_fig3_heptachlor,,OCP,one,heptachlor,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.34,0.48,2.2,NA,NA,53.5,,
KM,,completed,NA,lewis-mikhael_2015,ma_022,ma_m_056,fig3,lewis_mikhael_2015_fig3_lindane,,OCP,one,lindane,yes,no,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.56,0.82,2.29,NA,NA,41.7,,
KM,,completed,NA,wu_2013,ma_023,ma_m_057,fig2,wu_2013_fig2_DDE,,OCP,one,"p,p'-DDE",yes,,diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,not reported,OR (odds ratio),,,1.25,0.94,1.66,NA,NA,36.8,,
KM,,completed,NA,wu_2013,ma_023,ma_m_058,fig2,wu_2013_fig2_DDT,,OCP,one,"p,p'-DDT",yes,,diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,not reported,OR (odds ratio),,,1,0.54,1.87,NA,NA,0,,
KM,,completed,NA,wu_2013,ma_023,ma_m_059,fig2,wu_2013_fig2_HCB,,OCP,one,HCB,yes,,diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,,,fixed effects model,,not reported,OR (odds ratio),,,2,1.13,3.53,NA,NA,21.4,,
KM,,completed,NA,yang_2020,ma_024,ma_m_060,fig3a,yang_2020_fig3a,,OCP,one,beta-HCH,yes,,birth weight,,,,,,,fixed effects model,,not reported,adjusted coefficient regression (?),,,-22.96,-35.84,-10.07,NA,NA,36.12,,
KM,,completed,NA,liu_2022,ma_025,ma_m_061,fig4a,liu_2022_fig4,,OCP,multiple,combined ocp,yes,,CRP,,markers of inflammation,,,,,,,not reported,correlation coefficient (r) ,,,0.065,0.03,0.099,NA,NA,,,
KM,,completed,NA,liu_2022,ma_025,ma_m_062,fig4b,liu_2022_fig4,,OCP,multiple,combined ocp,yes,,IL-1?,,markers of inflammation,,,,,,,not reported,correlation coefficient (r) ,,,0.313,0.05,0.535,NA,NA,,,
KM,,completed,NA,liu_2022,ma_025,ma_m_063,fig4c,liu_2022_fig4,,OCP,multiple,combined ocp,yes,,IL-2,,markers of inflammation,,,,,,,not reported,correlation coefficient (r) ,,,0.062,0.004,0.12,NA,NA,,,
KM,,completed,NA,liu_2022,ma_025,ma_m_064,fig4d,liu_2022_fig4,,OCP,multiple,combined ocp,yes,,IL-10,,markers of inflammation,,,,,,,not reported,correlation coefficient (r) ,,,0.075,0.019,0.13,NA,NA,,,
KM,,completed,NA,canosancho_2019,ma_026,ma_m_065,fig7,canosancho_2019_fig7,,OCP,multiple,combined ocp,yes,,endometriosis,,reproductive disorders,,,,,random effects model,,DerSimonian and Laird,lnRR (risk ratio),,,0.21,0.12,0.31,NA,NA,50,,
KM,,completed,NA,maelefabry_2012,ma_027,ma_m_066,fig2,maelefabry_2012_fig2,,other,multiple,mixed pesticides,yes,,parkinsons disease,,neurological disorders,,,,,random effects model,,DerSimonian and Laird,rate ratio,,,1.28,1.03,1.59,NA,NA,74,,
KM,,completed,NA,jin_2014,ma_028,ma_m_067,fig2,jin_2014_fig2,,other,multiple,mixed pesticides,yes,,myelodysplastic syndromes,,cancer,,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.95,1.23,3.09,NA,NA,80.8,,
KM,,completed,NA,moore_2011,ma_029,ma_m_068,fig2,moore_2011_fig2,,other,multiple,mixed pesticides,yes,,neuroblastoma,,cancer,,,,,random effects model,,DerSimonian and Laird,RR (risk ratio),,,1.07,0.79,1.45,NA,NA,4.9,,
KM,,completed,NA,turner_2010,ma_030,ma_m_069,fig2a,turner_2010_fig2a,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.54,1.13,2.11,NA,NA,66,,
KM,,completed,NA,turner_2010,ma_030,ma_m_070,fig2b,turner_2010_fig2b,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,2.05,1.8,2.32,NA,NA,0,,
KM,,completed,NA,turner_2010,ma_030,ma_m_071,fig2c,turner_2010_fig2c,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.61,1.2,2.16,NA,NA,0,,
KM,,completed,NA,turner_2010,ma_030,ma_m_072,fig3a,turner_2010_fig3a,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.38,1.12,1.7,NA,NA,4,,
KM,,completed,NA,turner_2010,ma_030,ma_m_073,fig3b,turner_2010_fig3b,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.61,1.33,1.95,NA,NA,0,,
KM,,completed,NA,turner_2010,ma_030,ma_m_074,fig3c,turner_2010_fig3c,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,0.96,0.59,1.58,NA,NA,72,,
KM,,completed,NA,karalexi_2021,ma_031,ma_m_075,fig2a,karalexi_2021_fig2a,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.75,1.08,2.85,NA,NA,78.2,,
KM,,completed,NA,karalexi_2021,ma_031,ma_m_076,fig2b,karalexi_2021_fig2b,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.2,1.07,1.35,NA,NA,6.2,,
KM,,completed,NA,karalexi_2021,ma_031,ma_m_077,fig2c,karalexi_2021_fig2c,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.02,0.76,1.36,NA,NA,39.7,,
KM,,completed,NA,karalexi_2021,ma_031,ma_m_078,fig3a,karalexi_2021_fig3a,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.88,1.15,3.08,NA,NA,51.3,,
KM,,completed,NA,karalexi_2021,ma_031,ma_m_079,fig3b,karalexi_2021_fig3b,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,2.08,1.69,2.56,NA,NA,11.9,,
KM,,completed,NA,karalexi_2021,ma_031,ma_m_080,fig4,karalexi_2021_fig4,,other,multiple,mixed pesticides,yes,,leukemia ,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.82,1.07,3.11,NA,NA,80.6,,
KM,,completed,NA,maelefabry_2013,ma_032,ma_m_081,fig1,maelefabry_2013_fig1a,,other,multiple,mixed pesticides,yes,,brain tumour,,neurological disorders,,children,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.3,1.11,1.53,NA,NA,0,,
KM,,completed,NA,maelefabry_2013,ma_032,ma_m_082,fig1,maelefabry_2013_fig1b,,other,multiple,mixed pesticides,yes,,brain tumour,,neurological disorders,,,,,random effects model,,DerSimonian and Laird,rate ratio ,,,1.53,1.2,1.95,NA,NA,15,,
KM,,completed,NA,yan_2016,ma_033,ma_m_083,fig2a,yan_2016_fig2a,,other,multiple,mixed pesticides,yes,,alzheimers disease,,neurological disorders,,,,,random effects model,,not reported,OR (odds ratio),,,1.37,1.08,1.75,NA,NA,0,,
,,,,yan_2016,ma_033,ma_m_084,fig2a,yan_2016_fig2b,,other,multiple,mixed pesticides,yes,,alzheimers disease,,neurological disorders,,,,,random effects model,,not reported,OR (odds ratio),,,1.24,0.78,1.97,NA,NA,0,,
KM,,completed,NA,maelefabry_2019,ma_034,ma_m_085,fig2a,maelefabry_2019,,other,multiple,mixed pesticides,yes,,leukemia,,cancer,,childhood,,,random effects model,,DerSimonian and Laird,RR (risk ratio),,,1.57,1.27,1.95,NA,NA,73,,
KM,,completed,NA,yan_2018,ma_035,ma_m_086,fig3 ,,,other,multiple,mixed pesticides,yes,,parkinsons disease,,neurological disorders,,,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.01,1,1.02,NA,NA,53.8,,
KM,,completed,NA,wei_2018,ma_036,ma_m_087,fig2,,,other,multiple,mixed pesticides,yes,,pancreatic cancer,,cancer,,,,,random effects model,,not reported,OR (odds ratio),,,1.02,0.69,1.35,NA,NA,62.1,,
KM,,completed,NA,maelefabry_2017,ma_037,ma_m_088,fig2,,,other,multiple,mixed pesticides,yes,,brain tumour,,neurological disorders,,children,,,random effects model,,DerSimonian and Laird,OR (odds ratio),,,1.26,1.13,1.4,NA,NA,0,,
KM,,completed,NA,wang_2017,ma_038,ma_m_089,fig2,,,other,multiple,mixed pesticides,yes,,amyotrophic lateral sclerosis,,neurological disorders,,,,,random effects model,,Mantel-Haenszel,OR (odds ratio),,,1.57,1.25,1.98,NA,NA,42,,
KM,,completed,NA,chen_2015,ma_039,ma_m_090,fig3a,,,other,multiple,mixed pesticides,yes,,brain tumour,,neurological disorders,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.54,1.13,2.11,NA,NA,66,,
KM,,completed,NA,chen_2015,ma_039,ma_m_091,fig3b,,,other,multiple,mixed pesticides,yes,,leukemia,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,2.05,1.8,2.32,NA,NA,0,,
KM,,completed,NA,chen_2015,ma_039,ma_m_092,fig3c,,,other,multiple,mixed pesticides,yes,,lymphoma,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.61,1.2,2.16,NA,NA,0,,
KM,,completed,NA,chen_2015,ma_039,ma_m_093,fig4a,,,other,multiple,mixed pesticides,yes,,brain tumour,,neurological disorders,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.38,1.12,1.7,NA,NA,4,,
KM,,completed,NA,chen_2015,ma_039,ma_m_094,fig4b,,,other,multiple,mixed pesticides,yes,,leukemia,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,1.61,1.33,1.95,NA,NA,0,,
KM,,completed,NA,chen_2015,ma_039,ma_m_095,fig4c,,,other,multiple,mixed pesticides,yes,,lymphoma,,cancer,,childhood,,,random effects model,,not reported,OR (odds ratio),,,0.96,0.59,1.58,NA,NA,72,,
KM,,completed,NA,maelefabry_2008,ma_040,ma_m_096,fig2,,,other,multiple,mixed pesticides,yes,,leukemia,,cancer,,,,,fixed effects model,,maximum likelihood estimate,relative risk,,,1.43,1.05,1.94,NA,NA,0,,
KM,,completed,overall estimate expressed in g birth weight/(ng/mL increase in serum or plasma PFOA),johnson_2014,ma_041,ma_m_097,fig5,,children,PFAS,one,PFOA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,9,random effects model,,DerSimonian and Laird,change in birth weight in grams per nanogram of PFOA per milliliter of serum or plasma,NA,NA,-18.9,-29.8,-7.9,NA,NA,38,NA,NA
KM,,completed,NA,liu_2018,ma_042,ma_m_098,fig2,,,PFAS,one,PFOA,yes,no,risk of overweight,5B80.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,6,7,random effects model,,not reported,relative risk,NA,NA,1.26,1.01,1.56,NA,NA,57.2,NA,NA
KM,,completed,NA,liu_2018,ma_042,ma_m_099,fig2,,,PFAS,one,PFOA,yes,no,risk of overweight,5B80.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,2,3,random effects model,,not reported,OR (odds ratio),NA,NA,1.39,0.85,2.28,NA,NA,0,NA,NA
KM,,completed,NA,liu_2018,ma_042,ma_m_100,fig3,,,PFAS,one,PFOA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,9,11,random effects model,,not reported,adjusted coefficient regression (?),logistic,"""We used multivariable logistic regression to estimate adjusted odds ratios (ORs)"". From Lauritzen HB, Larose TL, Oien T, et al. Prenatal exposure to persistent organic pollutants and child overweight/obesity at 5-year follow-up: a prospective cohort study. Environ Health. 2018;17(1):9.",0.1,0.03,0.17,NA,NA,27.9,NA,NA
KM,,completed,NA,cao_2021 ,ma_043,ma_m_101,fig2,,children,PFAS,one,PFOA,yes,no,low birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,reduced fetal growth,,7,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.9,0.8,1.01,NA,NA,18.4,NA,NA
KM,,completed,NA,cao_2021 ,ma_043,ma_m_102,fig3,,children,PFAS,one,PFOS,yes,no,low birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,reduced fetal growth,,5,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.32,1.09,1.55,NA,NA,0,NA,NA
KM,,completed,NA,wang_2022,ma_044,ma_m_103,fig2,,pregnant women,PFAS,one,PFOA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,8,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.27,1.02,1.59,NA,NA,0,NA,NA
KM,,completed,NA,wang_2022,ma_044,ma_m_104,fig3,,pregnant women,PFAS,one,PFOS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,8,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.97,0.86,1.09,NA,NA,10.5,NA,NA
KM,,completed,NA,wang_2022,ma_044,ma_m_105,fig4,,pregnant women,PFAS,one,PFHxS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,7,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.03,0.86,1.24,NA,NA,0,NA,NA
KM,,completed,NA,wang_2022,ma_044,ma_m_106,fig5,,pregnant women,PFAS,one,PFNA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,5,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.8,0.55,1.16,NA,NA,0,NA,NA
KM,,completed,NA,gui_2022,ma_045,ma_m_107,fig2,,children,PFAS,one,PFOS,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,23,random effects model,,DerSimonian and Laird,adjusted coefficient regression (?),linear,"""Associations between PFAS and birth weight and adiposity, and between PFAS and maternal glucose and lipids, were estimated via linear regression."" From Starling AP, Adgate JL, Hamman RF, Kechris K, Calafat AM, Ye X, et al. Perfluoroalkyl substances during pregnancy and offspring weight and adiposity at birth: examining mediation by maternal fasting glucose in the healthy start study. Environ Health Perspect. (2017) 125:067016. doi: 10.1289/EHP641",-34.88,-52.53,-17.24,NA,NA,66.2,NA,NA
KM,,completed,NA,gui_2022,ma_045,ma_m_108,fig2,,children,PFAS,one,PFOA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,26,random effects model,,DerSimonian and Laird,adjusted coefficient regression (?),linear,"""Associations between PFAS and birth weight and adiposity, and between PFAS and maternal glucose and lipids, were estimated via linear regression."" From Starling AP, Adgate JL, Hamman RF, Kechris K, Calafat AM, Ye X, et al. Perfluoroalkyl substances during pregnancy and offspring weight and adiposity at birth: examining mediation by maternal fasting glucose in the healthy start study. Environ Health Perspect. (2017) 125:067016. doi: 10.1289/EHP641",-37.02,-54.37,-19.66,NA,NA,56.5,NA,NA
KM,,completed,NA,gui_2022,ma_045,ma_m_109,fig3,,children,PFAS,one,PFNA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,15,random effects model,,DerSimonian and Laird,adjusted coefficient regression (?),linear,"""We analysed the associations between maternal serum levels of POPs and birth weight, length, head circumference and GA using linear regression analysis."" From Hjermitslev MH, Long M, Wielsøe M, Bonefeld-Jørgensen EC. Persistent organic pollutants in Greenlandic pregnant women and indices of foetal growth: The ACCEPT study. Sci Total Environ. (2020) 698:134118. doi: 10.1016/j.scitotenv.2019.134118",-28.31,-44.8,-11.82,NA,NA,31.6,NA,NA
KM,,completed,NA,gui_2022,ma_045,ma_m_110,fig3,,children,PFAS,one,PFUnDA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,13,random effects model,,DerSimonian and Laird,adjusted coefficient regression (?),linear,"""We analysed the associations between maternal serum levels of POPs and birth weight, length, head circumference and GA using linear regression analysis."" From Hjermitslev MH, Long M, Wielsøe M, Bonefeld-Jørgensen EC. Persistent organic pollutants in Greenlandic pregnant women and indices of foetal growth: The ACCEPT study. Sci Total Environ. (2020) 698:134118. doi: 10.1016/j.scitotenv.2019.134118",-16.48,-26.39,-6.58,NA,NA,1.1,NA,NA
KM,,completed,NA,gui_2022,ma_045,ma_m_111,fig3,,children,PFAS,one,PFDA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,11,random effects model,,DerSimonian and Laird,adjusted coefficient regression (?),linear,"""We analysed the associations between maternal serum levels of POPs and birth weight, length, head circumference and GA using linear regression analysis."" From Hjermitslev MH, Long M, Wielsøe M, Bonefeld-Jørgensen EC. Persistent organic pollutants in Greenlandic pregnant women and indices of foetal growth: The ACCEPT study. Sci Total Environ. (2020) 698:134118. doi: 10.1016/j.scitotenv.2019.134118",-24.25,-38.57,-9.93,NA,NA,4,NA,NA
KM,,completed,NA,qu_2021,ma_046,ma_m_112,fig2,,children,PFAS,one,PFOA,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,8,random effects model,,not reported,OR (odds ratio),NA,NA,1,0.75,1.25,NA,NA,76.6,NA,NA
KM,,completed,NA,qu_2021,ma_046,ma_m_113,fig2,,children,PFAS,one,PFOS,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,8,random effects model,,not reported,OR (odds ratio),NA,NA,1.01,0.88,1.14,NA,NA,54.7,NA,NA
KM,,completed,NA,qu_2021,ma_046,ma_m_114,fig2,,children,PFAS,one,PFHxS,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,4,random effects model,,not reported,OR (odds ratio),NA,NA,1.08,0.8,1.36,NA,NA,87.2,NA,NA
KM,,completed,NA,qu_2021,ma_046,ma_m_115,fig2,,children,PFAS,one,PFNA,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,5,random effects model,,not reported,OR (odds ratio),NA,NA,1.13,0.99,1.28,NA,NA,0,NA,NA
KM,,completed,NA,qu_2021,ma_046,ma_m_116,fig2,,children,PFAS,one,PFDA,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.23,0.15,2.32,NA,NA,81.4,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_117,fig2a,,children,PFAS,one,PFDA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,3,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.97,0.83,1.14,NA,NA,40.5,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_118,fig2b,,children,PFAS,one,PFHxS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,6,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.98,0.9,1.08,NA,NA,7.2,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_119,fig2c,,children,PFAS,one,PFNA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,5,random effects model,,not reported,OR (odds ratio),NA,NA,1.22,0.94,1.58,NA,NA,60.1,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_120,fig2d,,children,PFAS,one,PFOA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,8,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.98,0.96,1,NA,NA,7.2,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_121,fig2e,,children,PFAS,one,PFOS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,8,random effects model,,not reported,OR (odds ratio),NA,NA,1,0.98,1.03,NA,NA,53.7,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_122,fig4a,,pregnant women,PFAS,one,PFOSA-AcOH,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.01,0.85,1.21,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_123,fig4b,,pregnant women,PFAS,one,n-PFOA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.1,0.96,1.25,NA,NA,29.2,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_124,fig4c,,pregnant women,PFAS,one,n-PFOS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.06,0.85,1.32,NA,NA,68.5,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_125,fig4d,,pregnant women,PFAS,one,PFDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,4,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.06,0.87,1.29,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_126,fig4e,,pregnant women,PFAS,one,PFHxS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,7,fixed effects model,,not reported,OR (odds ratio),NA,NA,1,0.96,1.04,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_127,fig4f,,pregnant women,PFAS,one,PFNA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,6,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.91,0.78,1.05,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_128,fig4g,,pregnant women,PFAS,one,PFOA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,7,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.03,0.99,1.07,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_129,fig4h,,pregnant women,PFAS,one,PFOS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,7,fixed effects model,,not reported,OR (odds ratio),NA,NA,1,0.99,1.01,NA,NA,10,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_130,fig4i,,pregnant women,PFAS,one,PFUnDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,3,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.04,0.78,1.39,NA,NA,0.5,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_131,fig5a,,pregnant women,PFAS,one,PFDA,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",Miscarriage was defined as a gestational age of loss ?22 weeks.,,2,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.87,1.15,3.03,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_132,fig5b,,pregnant women,PFAS,one,PFHxS,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",Miscarriage was defined as a gestational age of loss ?22 weeks.,,2,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.03,0.92,1.16,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_133,fig5c,,pregnant women,PFAS,one,PFNA,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",Miscarriage was defined as a gestational age of loss ?22 weeks.,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.57,0.85,2.88,NA,NA,52.4,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_134,fig5d,,pregnant women,PFAS,one,PFOA,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",Miscarriage was defined as a gestational age of loss ?22 weeks.,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.04,0.92,1.18,NA,NA,65.3,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_135,fig5e,,pregnant women,PFAS,one,PFOS,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",Miscarriage was defined as a gestational age of loss ?22 weeks.,,2,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.01,1,1.02,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_136,fig6a,,pregnant women,PFAS,one,PFDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,3,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.92,0.8,1.06,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_137,fig6b,,pregnant women,PFAS,one,PFHpA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,2,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.9,0.66,1.22,NA,NA,67.1,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_138,fig6c,,pregnant women,PFAS,one,PFHxS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,4,random effects model,,not reported,OR (odds ratio),NA,NA,1.1,0.95,1.26,NA,NA,37.4,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_139,fig6d,,pregnant women,PFAS,one,PFNA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,3,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.03,0.76,1.4,NA,NA,61.1,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_140,fig6e,,pregnant women,PFAS,one,PFOA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,4,random effects model,,not reported,OR (odds ratio),NA,NA,1.09,0.9,1.33,NA,NA,28.7,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_141,fig6f,,pregnant women,PFAS,one,PFOS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,4,fixed effects model,,not reported,OR (odds ratio),NA,NA,1.27,1.06,1.51,NA,NA,0,NA,NA
KM,,completed,NA,gao_2021,ma_047,ma_m_142,fig6g,,pregnant women,PFAS,one,PFUnDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,3,fixed effects model,,not reported,OR (odds ratio),NA,NA,0.81,0.71,0.93,NA,NA,0,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_143,fig3a,,rodents,PFAS,one,PFOA,yes,yes,testosterone,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,random effects model,,not reported,SMD (standardized mean difference),NA,NA,-0.54,-0.95,-0.13,NA,NA,71,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_144,fig3b,,rodents,PFAS,one,PFOA,yes,yes,estradiol,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,random effects model,,not reported,SMD (standardized mean difference),NA,NA,4.75,2.29,7.21,NA,NA,91,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_145,fig4a,,rodents,PFAS,one,PFOA,yes,yes,testicular weight,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,fixed effects model,,not reported,SMD (standardized mean difference),NA,NA,-0.2,-0.33,-0.06,NA,NA,44,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_146,fig4b,,rodents,PFAS,one,PFOA,yes,yes,epididymis weight,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,fixed effects model,,not reported,SMD (standardized mean difference),NA,NA,-0.5,-0.07,-0.34,NA,NA,39,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_147,fig4c,,rodents,PFAS,one,PFOA,yes,yes,relative testicular weight,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,random effects model,,not reported,SMD (standardized mean difference),NA,NA,0.03,0.01,0.04,NA,NA,78,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_148,fig4d,,rodents,PFAS,one,PFOA,yes,yes,relative seminal vesicles weight,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,random effects model,,not reported,SMD (standardized mean difference),NA,NA,0.61,0.17,1.05,NA,NA,84,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_149,fig4e,,rodents,PFAS,one,PFOA,yes,no,the day of preputial separation of pups,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,random effects model,,not reported,SMD (standardized mean difference),NA,NA,-0.44,-2.2,1.33,NA,NA,96,NA,NA
KM,,excluded,Rodent study so may be excluded for the MMA,wang_2021,ma_048,ma_m_150,fig5,,rodents,PFAS,one,PFOA,yes,no,semen parameters,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,,fixed effects model,,not reported,SMD (standardized mean difference),NA,NA,2.29,-0.03,4.61,NA,NA,54,NA,NA
KM,,completed,NA,jeddi_2021,ma_049,ma_m_151,fig2a,,adults,PFAS,one,PFOA,yes,no,risk of metabolic syndrome,5A44,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,,7,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.06,0.91,1.23,NA,NA,67.6,NA,NA
KM,,completed,NA,jeddi_2021,ma_049,ma_m_152,fig2b,,adults,PFAS,one,PFOS,yes,no,risk of metabolic syndrome,5A44,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,,7,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.94,0.79,1.1,NA,NA,78.7,NA,NA
KM,,completed,NA,jeddi_2021,ma_049,ma_m_153,fig2c,,adults,PFAS,one,PFNA,yes,no,risk of metabolic syndrome,5A44,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,,5,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.08,0.86,1.36,NA,NA,78,NA,NA
KM,,completed,NA,jeddi_2021,ma_049,ma_m_154,fig2d,,adults,PFAS,one,PFHxS,yes,no,risk of metabolic syndrome,5A44,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,,5,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.99,0.94,1.04,NA,NA,23,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_155,fig2a,,children,PFAS,multiple,PFAS,yes,no,asthma,CA23.0,Certain lower respiratory tract diseases,Diseases of the respiratory system,Allergic asthma,,8,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.11,0.88,1.4,NA,NA,62.1,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_156,fig2b,,children,PFAS,one,PFOS,yes,no,asthma,CA23.0,Certain lower respiratory tract diseases,Diseases of the respiratory system,Allergic asthma,,8,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.11,0.86,1.43,NA,NA,73.1,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_157,fig2c,,children,PFAS,one,PFHxS,yes,no,asthma,CA23.0,Certain lower respiratory tract diseases,Diseases of the respiratory system,Allergic asthma,,8,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.02,0.85,1.24,NA,NA,68.8,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_158,fig2d,,children,PFAS,one,PFNA,yes,no,asthma,CA23.0,Certain lower respiratory tract diseases,Diseases of the respiratory system,Allergic asthma,,8,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.99,0.81,1.21,NA,NA,65.5,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_159,fig3a,,children,PFAS,multiple,PFAS,yes,no,eczema,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,5,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.91,0.81,1.02,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_160,fig3b,,children,PFAS,one,PFOS,yes,no,eczema,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,5,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.99,0.88,1.1,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_161,fig3c,,children,PFAS,one,PFHxS,yes,no,eczema,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,5,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.07,0.96,1.2,NA,NA,32.8,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_162,fig3d,,children,PFAS,one,PFNA,yes,no,eczema,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,5,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.89,0.8,0.99,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_163,fig4a,,children,PFAS,multiple,PFAS,yes,yes,wheeze,MD11.C,"Symptoms, signs or clinical findings of the respiratory system","Symptoms, signs or clinical findings, not elsewhere classified",NA,,6,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.9,0.78,1.04,NA,NA,24.7,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_164,fig4b,,children,PFAS,one,PFOS,yes,yes,wheeze,MD11.C,"Symptoms, signs or clinical findings of the respiratory system","Symptoms, signs or clinical findings, not elsewhere classified",NA,,6,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.03,0.93,1.15,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_165,fig4c,,children,PFAS,one,PFHxS,yes,yes,wheeze,MD11.C,"Symptoms, signs or clinical findings of the respiratory system","Symptoms, signs or clinical findings, not elsewhere classified",NA,,6,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.97,0.87,1.08,NA,NA,20.8,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_166,fig4d,,children,PFAS,one,PFNA,yes,yes,wheeze,MD11.C,"Symptoms, signs or clinical findings of the respiratory system","Symptoms, signs or clinical findings, not elsewhere classified",NA,,6,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.98,0.88,1.08,NA,NA,3.4,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_167,fig5a,,children,PFAS,multiple,PFAS,yes,no,atopic dermatitis,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.26,1.01,1.58,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_168,fig5b,,children,PFAS,one,PFOS,yes,no,atopic dermatitis,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.39,0.89,2.18,NA,NA,62,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_169,fig5c,,children,PFAS,one,PFHxS,yes,no,atopic dermatitis,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,3,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.08,0.92,1.27,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_170,fig5d,,children,PFAS,one,PFNA,yes,no,atopic dermatitis,EA80.1,Inflammatory dermatoses,Diseases of the skin,Childhood atopic eczema,,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.96,0.65,1.43,NA,NA,48.8,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_171,fig6a,,children,PFAS,multiple,PFAS,yes,no,allergic rhinitis,CA08.0Z,Upper respiratory tract disorders,Diseases of the respiratory system,"Allergic rhinitis, unspecified",,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.07,0.89,1.29,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_172,fig6b,,children,PFAS,one,PFOS,yes,no,allergic rhinitis,CA08.0Z,Upper respiratory tract disorders,Diseases of the respiratory system,"Allergic rhinitis, unspecified",,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,1.32,1.13,1.55,NA,NA,0,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_173,fig6c,,children,PFAS,one,PFHxS,yes,no,allergic rhinitis,CA08.0Z,Upper respiratory tract disorders,Diseases of the respiratory system,"Allergic rhinitis, unspecified",,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.94,0.79,1.13,NA,NA,23.1,NA,NA
KM,,completed,NA,luo_2020,ma_050,ma_m_174,fig6d,,children,PFAS,one,PFNA,yes,no,allergic rhinitis,CA08.0Z,Upper respiratory tract disorders,Diseases of the respiratory system,"Allergic rhinitis, unspecified",,4,random effects model,,DerSimonian and Laird,OR (odds ratio),NA,NA,0.99,0.71,1.37,NA,NA,69.2,NA,NA
KM,,completed,NA,dzierlanga_2020,ma_051,ma_m_175,fig2,,children,PFAS,one,PFOS,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,,random effects model,,not reported,? (regression coefficient) value,linear,"""Because ignoring the sampling scheme can lead to biased results, we accounted for sampling selection probabilities by constructing stratum-weighted linear and longitudinal regression models to estimate the associations between PFC concentrations and fetal and postnatal growth"" From Maisonet M, Terrell ML, McGeehin MA, et al. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect. 2012;120:1432–1437.",-3.22,-5.108,-1.331,NA,NA,NA,NA,74.5
KM,,completed,NA,kim_2018,ma_052,ma_m_176,fig2a,,adults,PFAS,one,PFOS,yes,yes,free t4,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,0.05,0.03,0.08,NA,NA,0,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_177,fig2b,,adults,PFAS,one,PFOS,yes,yes,total t4,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,0.01,-0.05,0.07,NA,NA,70,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_178,fig2c,,adults,PFAS,one,PFOS,yes,yes,total t3,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,-0.02,-0.07,0.04,NA,NA,63,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_179,fig2d,,adults,PFAS,one,PFOS,yes,yes,TSH,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,-0.02,-0.07,0.03,NA,NA,71,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_180,fig3a,,adults,PFAS,one,PFOA,yes,yes,free t4,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,0.01,-0.02,0.04,NA,NA,0,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_181,fig3b,,adults,PFAS,one,PFOA,yes,yes,total t4,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,-0.01,-0.07,0.05,NA,NA,66,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_182,fig3c,,adults,PFAS,one,PFOA,yes,yes,total t3,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,0.05,0,0.1,NA,NA,43,NA,NA
KM,,completed,NA,kim_2018,ma_052,ma_m_183,fig3d,,adults,PFAS,one,PFOA,yes,yes,TSH,5A61.4,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Thyroid stimulating hormone deficiency,,,random effects model,,not reported,fishers z ,NA,NA,0,-0.03,0.04,NA,NA,30,NA,NA
KM,,completed,NA,verner_2015,ma_053,ma_m_184,fig3a,,children,PFAS,one,PFOA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,,not reported ,,not reported,adjusted coefficient regression (?),linear and longitudinal,"""Because ignoring the sampling scheme can lead to biased results, we accounted for sampling selection probabilities by constructing stratum-weighted linear and longitudinal regression models to estimate the associations between PFC concentrations and fetal and postnatal growth (Richardson et al. 2007)."" From Maisonet M, Terrell ML, McGeehin MA, Christensen KY, Holmes A, Calafat AMet al. 2012. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect 120:1432-1437; https://doi.org/10.1289/ehp.1003096 https://pubmed.ncbi.nlm.nih.gov/22935244/.",-14.72,-21.66,-7.78,NA,NA,7.4,NA,NA
KM,,completed,NA,verner_2015,ma_053,ma_m_185,fig3b,,children,PFAS,one,PFOS,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,,not reported ,,not reported,adjusted coefficient regression (?),linear and longitudinal,"""Because ignoring the sampling scheme can lead to biased results, we accounted for sampling selection probabilities by constructing stratum-weighted linear and longitudinal regression models to estimate the associations between PFC concentrations and fetal and postnatal growth (Richardson et al. 2007)."" From Maisonet M, Terrell ML, McGeehin MA, Christensen KY, Holmes A, Calafat AMet al. 2012. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect 120:1432-1437; https://doi.org/10.1289/ehp.1003096 https://pubmed.ncbi.nlm.nih.gov/22935244/.",-5,-8.92,-1.09,NA,NA,20.1,NA,NA
KM,,completed,NA,bliatka_2020,ma_054,ma_m_186,,,,other,multiple,general edc,yes,,testicular function,,reproductive disorders,,,,,random effects model,,DerSimonian and Laird,SMD (standardized mean difference),,,-0.17,-0.33,-0.02,NA,NA,40,,
KM,,completed,NA,jiang_2022,ma_055,ma_m_187,fig2a,,women,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,19,random effects model,,not reported,OR (odds ratio),NA,NA,1.32,1.19,1.46,NA,NA,98.5,NA,NA
KM,,completed,NA,jiang_2022,ma_055,ma_m_188,fig2b,,women,PFAS,one,PFNA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,15,random effects model,,not reported,OR (odds ratio),NA,NA,0.76,0.6,0.96,NA,NA,99.9,NA,NA
KM,,completed,NA,jiang_2022,ma_055,ma_m_189,fig2c,,women,PFAS,one,PFHxS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,15,random effects model,,not reported,OR (odds ratio),NA,NA,1.79,1.51,2.11,NA,NA,99.3,NA,NA
KM,,completed,NA,jiang_2022,ma_055,ma_m_190,fig2d,,women,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,19,random effects model,,not reported,OR (odds ratio),NA,NA,1.01,0.87,1.17,NA,NA,99.8,NA,NA
KM,,excluded,animal study ,banyoi_2022,ma_056,ma_m_191,,,,PFAS,,,,,,,,,,,,random effects model,,not reported,SMD (standardized mean difference),,,-0.72,-1.08,-0.36,NA,NA,,,
KM,,excluded,animal study ,banyoi_2022,ma_056,ma_m_192,,,,PFAS,,,,,,,,,,,,random effects model,,not reported,SMD (standardized mean difference),,,-1.24,-2.26,-0.21,NA,NA,,,
KM,,excluded,animal study ,banyoi_2022,ma_056,ma_m_193,,,,PFAS,,,,,,,,,,,,random effects model,,not reported,SMD (standardized mean difference),,,-1.51,-3.05,0.03,NA,NA,,,
KM,,excluded,animal study ,banyoi_2022,ma_056,ma_m_194,,,,PFAS,,,,,,,,,,,,random effects model,,not reported,SMD (standardized mean difference),,,-0.36,-0.62,-0.09,NA,NA,,,
KM,,excluded,animal study ,banyoi_2022,ma_056,ma_m_195,,,,PFAS,,,,,,,,,,,,random effects model,,not reported,SMD (standardized mean difference),,,-0.42,-0.67,-0.16,NA,NA,,,
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_196,,,children,PFAS,one,PFDA,yes,no,diphtheria,1C17.Z,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-10.3,-23.46,2.86,NA,NA,NA,NA,9.44
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_197,,,children,PFAS,one,PFDA,yes,no,tetanus,1C13,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-6.95,-21.09,7.19,NA,NA,NA,NA,8.23
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_198,,,children,PFAS,one,PFNA,yes,no,diphtheria,1C17.Z,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-7.31,-22.37,7.75,NA,NA,NA,NA,10.3
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_199,,,children,PFAS,one,PFNA,yes,no,tetanus,1C13,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-7.76,-18.6,3.07,NA,NA,NA,NA,4.72
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_200,,,children,PFAS,one,PFHxS,yes,no,diphtheria,1C17.Z,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-3.81,-13.71,6.1,NA,NA,NA,NA,11.82
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_201,,,children,PFAS,one,PFHxS,yes,no,tetanus,1C13,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-9.37,-18.64,-0.1,NA,NA,NA,NA,10.33
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_202,,,children,PFAS,one,PFOA,yes,no,diphtheria,1C17.Z,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-9.24,-23.25,4.76,NA,NA,NA,NA,10.22
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_203,,,children,PFAS,one,PFOA,yes,no,tetanus,1C13,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-20.11,-29.45,-10.77,NA,NA,NA,NA,5.26
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_204,,,children,PFAS,one,PFOS,yes,no,diphtheria,1C17.Z,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-13.6,-31.43,4.22,NA,NA,NA,NA,16.11
KM,,excluded,"""Summary results of mean difference (MD) of percentage change, regression coefficient (?), Spearman correlation coefficient (R), and 95% confidence intervals (CIs) were extracted from each study to assess the relationships between PFAS exposure levels and vaccine antibody concentrations."" and ""For the expression of the association between PFAS exposure and vaccine antibodies, the indicators used in these papers were MD of percentage change, ?, OR, and R. """,zhang_2022,ma_057,ma_m_205,,,children,PFAS,one,PFOS,yes,no,tetanus,1C13,Other bacterial diseases,Certain infectious or parasitic diseases,vaccine antibody levels,,,random effects model,,DerSimonian and Laird,unclear,NA,NA,-10.04,-19.12,-0.96,NA,NA,NA,NA,3.07
KM,,completed,NA,yan_2022,ma_058,ma_m_206,fig5,,pregnant women,PFAS,one,PFHxS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,8,random effects model,,not reported,OR (odds ratio),NA,NA,1.07,0.94,1.23,NA,NA,0,NA,NA
KM,,completed,NA,yan_2022,ma_058,ma_m_207,fig5,,pregnant women,PFAS,one,PFDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,6,random effects model,,not reported,OR (odds ratio),NA,NA,0.96,0.82,1.13,NA,NA,0,NA,NA
KM,,completed,NA,yan_2022,ma_058,ma_m_208,fig5,,pregnant women,PFAS,one,PFNA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,8,random effects model,,not reported,OR (odds ratio),NA,NA,0.98,0.84,1.16,NA,NA,0,NA,NA
KM,,completed,NA,yan_2022,ma_058,ma_m_209,fig5,,pregnant women,PFAS,one,PFOA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,11,random effects model,,not reported,OR (odds ratio),NA,NA,1.14,1.02,1.28,NA,NA,19.5,NA,NA
KM,,completed,NA,yan_2022,ma_058,ma_m_210,fig5,,pregnant women,PFAS,one,PFOS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,11,random effects model,,not reported,OR (odds ratio),NA,NA,1.01,0.92,1.11,NA,NA,25.3,NA,NA
KM,,completed,NA,yan_2022,ma_058,ma_m_211,fig5,,pregnant women,PFAS,one,PFUnDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,3,random effects model,,not reported,OR (odds ratio),NA,NA,0.9,0.74,1.09,NA,NA,29.9,NA,NA
KM,,completed,NA,yan_2022,ma_058,ma_m_212,fig5,,pregnant women,PFAS,one,PFBS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.34,1.17,1.53,NA,NA,76.4,NA,NA
KM,,completed,this is split for some unclear reason,yan_2022,ma_058,ma_m_213,fig5,,pregnant women,PFAS,one,PFDoDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.12,0.89,1.39,NA,NA,86.4,NA,NA
KM,,completed,this is split for some unclear reason,yan_2022,ma_058,ma_m_214,fig5,,pregnant women,PFAS,one,PFDoDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.29,0.93,1.8,NA,NA,0,NA,NA
KM,,completed,this is split for some unclear reason,yan_2022,ma_058,ma_m_215,fig5,,pregnant women,PFAS,one,PFDoDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,,2,random effects model,,not reported,OR (odds ratio),NA,NA,1.12,0.8,1.55,NA,NA,0,NA,NA
KM,,completed,NA,wang_2022,ma_059,ma_m_216,tab2,,women,PFAS,one,PFOA,yes,no,fecundability,NA,NA,"Pregnancy, childbirth or the puerperium","Fecundability is the probability of conception after a couple has regular intercourse without contraception during a cycle, which was always assessed by time-to-pregnancy (TTP) index from a prospective design.",10,,random effects model,,inverse variance,OR (odds ratio),NA,NA,0.88,0.78,0.98,NA,NA,63,NA,NA
KM,,completed,NA,wang_2022,ma_059,ma_m_217,tab2,,women,PFAS,one,PFOA,yes,no,infertility,NA,NA,"Pregnancy, childbirth or the puerperium",Infertility defined as a time-to-pregnancy (TTP) >12 months or infertility treatment prior to current pregnancy,9,,random effects model,,inverse variance,OR (odds ratio),NA,NA,1.33,1.03,1.73,NA,NA,63,NA,NA
KM,,completed,NA,wang_2022,ma_059,ma_m_218,tab2,,women,PFAS,one,PFOS,yes,no,fecundability,NA,NA,"Pregnancy, childbirth or the puerperium","Fecundability is the probability of conception after a couple has regular intercourse without contraception during a cycle, which was always assessed by time-to-pregnancy (TTP) index from a prospective design.",10,,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,0.94,0.9,0.98,NA,NA,39,NA,NA
KM,,completed,NA,wang_2022,ma_059,ma_m_219,tab2,,women,PFAS,one,PFOS,yes,no,infertility,NA,NA,"Pregnancy, childbirth or the puerperium",Infertility defined as a time-to-pregnancy (TTP) >12 months or infertility treatment prior to current pregnancy,9,,random effects model,,inverse variance,OR (odds ratio),NA,NA,1.18,0.94,1.5,NA,NA,55,NA,NA
LR,,completed,NA,wang_2022,ma_059,ma_m_220,tab2,,women,PFAS,one,PFNA,yes,no,fecundability,NA,NA,"Pregnancy, childbirth or the puerperium","Fecundability is the probability of conception after a couple has regular intercourse without contraception during a cycle, which was always assessed by time-to-pregnancy (TTP) index from a prospective design.",10,,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,0.99,0.91,1.08,NA,NA,40,NA,
LR,,completed,NA,wang_2022,ma_059,ma_m_221,tab2,,women,PFAS,one,PFNA,yes,no,infertility,NA,NA,"Pregnancy, childbirth or the puerperium",Infertility defined as a time-to-pregnancy (TTP) >12 months or infertility treatment prior to current pregnancy,5,,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,0.83,0.65,1.06,NA,NA,50,NA,
LR,,completed,NA,wang_2022,ma_059,ma_m_222,tab2,,women,PFAS,one,PFDA,yes,no,fecundability,NA,NA,"Pregnancy, childbirth or the puerperium","Fecundability is the probability of conception after a couple has regular intercourse without contraception during a cycle, which was always assessed by time-to-pregnancy (TTP) index from a prospective design.",4,,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,1.04,0.94,1.14,NA,NA,43,NA,
LR,,completed,NA,wang_2022,ma_059,ma_m_223,tab2,,women,PFAS,one,PFDA,yes,no,infertility,NA,NA,"Pregnancy, childbirth or the puerperium",Infertility defined as a time-to-pregnancy (TTP) >12 months or infertility treatment prior to current pregnancy,4,,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,0.76,0.57,1.02,NA,NA,7,NA,
LR,,completed,NA,wang_2022,ma_059,ma_m_224,tab2,,women,PFAS,one,PFHxS,yes,no,fecundability,NA,NA,"Pregnancy, childbirth or the puerperium","Fecundability is the probability of conception after a couple has regular intercourse without contraception during a cycle, which was always assessed by time-to-pregnancy (TTP) index from a prospective design.",7,,random effects model,,inverse variance,OR (odds ratio),NA,NA,0.96,0.86,1.08,NA,NA,57,NA,
LR,,completed,NA,wang_2022,ma_059,ma_m_225,tab2,,women,PFAS,one,PFHxS,yes,no,infertility,NA,NA,"Pregnancy, childbirth or the puerperium",Infertility defined as a time-to-pregnancy (TTP) >12 months or infertility treatment prior to current pregnancy,6,,random effects model,,inverse variance,OR (odds ratio),NA,NA,0.91,0.66,1.24,NA,NA,67,NA,
KM,,excluded,NA,hirke_2022,ma_060,ma_m_226,fig2A,,pregnant women,PFAS,one,PFOA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,8,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,1.2,1.04,1.39,NA,NA,0,NA,NA
KM,,excluded,NA,hirke_2022,ma_060,ma_m_227,fig2B,,pregnant women,PFAS,one,PFOS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,8,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,1.23,1.1,1.38,NA,NA,0,NA,NA
KM,,excluded,NA,hirke_2022,ma_060,ma_m_228,fig2C,,pregnant women,PFAS,one,PFNA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,,6,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,1.2,1.03,1.4,NA,NA,0,NA,NA
KM,,excluded,NA,hirke_2022,ma_060,ma_m_229,fig4A,,pregnant women,PFAS,one,PFOA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,,4,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,1.18,1.01,1.39,NA,NA,35,NA,NA
KM,,excluded,NA,hirke_2022,ma_060,ma_m_230,fig4B,,pregnant women,PFAS,one,PFHxS,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,,4,fixed effects model,,inverse variance,OR (odds ratio),NA,NA,1.15,1.02,1.29,NA,NA,49,NA,NA
KM,,completed,NA,brauner_2021,ma_061,ma_m_231,fig4a,brauner_2021_fig4a,,OCP,multiple,combined ocp,yes,,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,maternal exposure,,,random effects model,,not reported,hazard ratio,,,1.61,0.99,2.61,NA,NA,66,,
KM,,completed,NA,brauner_2021,ma_061,ma_m_232,fig4b,brauner_2021_fig4b,,OCP,multiple,combined ocp,yes,,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,male exposure,,,random effects model,,not reported,hazard ratio,,,1.24,1.11,1.39,NA,NA,9,,
KM,,completed,NA,adami_1995,ma_062,ma_m_233,,,,OCP,one,DDE,yes,,estrogen related cancer,,cancer,,,,,not reported ,,not reported ,ratio of means,,,1.08,0.98,1.19,NA,NA,,,
KM,,completed,NA,wang_2016,ma_063,ma_m_234,fig3,,,OCP,multiple,combined ocp,yes,,sperm quality ,,reproductive disorders,,,,,fixed effects model,,not reported,OR (odds ratio),,,1.98,1.34,2.62,NA,NA,0,,
LR,,excluded,NA,rosato_2024,ma_064,ma_m_235,fig2,,,PFAS,one,PFOA,no,,half life,,,,NA,,7,random effects model,NA,not reported,half-life estimation,,,2.75,1.88,3.63,NA,NA,93,,NA
LR,,excluded,NA,rosato_2024,ma_064,ma_m_236,fig3,,,PFAS,one,PFOS,no,,half life,,,,NA,,3,random effects model,NA,not reported,half-life estimation,,,4.77,3.26,6.29,NA,NA,97,,NA
LR,,excluded,NA,rosato_2024,ma_064,ma_m_237,fig3,,,PFAS,one,PFHxS,no,,half life,,,,NA,,4,random effects model,NA,not reported,half-life estimation,,,5.35,3.16,7.55,NA,NA,93,,NA
LR,,excluded,"EXCLUDE IT. The review combined results on different effect sizes (OR, RR, HR).",timmerman_2023,,ma_m_238,,,,,,,,,,,,,,,,not reported ,,not reported,"hazard ratios (HR), relative risks (RR), and odds ratios (OR)",,,,,,,,,,
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_239,fig2,liu_2023a_fig2,,OCP,one,"p,p'-DDT",yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,25,random effects model,NA,not reported,OR (odds ratio),,,1.22,1.03,1.45,NA,NA,77.7,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_240,fig3,liu_2023a_fig3,,OCP,one,"p,p'-DDE",yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,34,random effects model,NA,not reported,OR (odds ratio),,,1.15,1.01,1.3,NA,NA,59.9,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_241,fig4,liu_2023a_fig4,,OCP,one,HCB,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,14,random effects model,NA,not reported,OR (odds ratio),,,1.06,0.68,1.65,NA,NA,77.4,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_242,fig5,liu_2023a_fig5,,OCP,one,HCH,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,22,random effects model,NA,not reported,OR (odds ratio),,,1.33,1.05,1.67,NA,NA,70.3,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_243,fig7a,liu_2023a_fig7a,,other,one,PCB99,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,6,random effects model,NA,not reported,OR (odds ratio),,,1.43,1.17,1.76,NA,NA,0,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_244,fig7b,liu_2023a_fig7b,,other,one,PCB105,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,4,random effects model,NA,not reported,OR (odds ratio),,,2.05,1.42,2.97,NA,NA,0,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_245,fig7c,liu_2023a_fig7c,,other,one,PCB183,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,7,random effects model,NA,not reported,OR (odds ratio),,,1.57,1.27,1.94,NA,NA,0,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_246,fig7d,liu_2023a_fig7d,,other,one,PCB138,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,13,random effects model,NA,not reported,OR (odds ratio),,,1.33,1.1,1.6,NA,NA,52.9,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_247,fig7e,liu_2023a_fig7e,,other,one,PCB118,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,14,random effects model,NA,not reported,OR (odds ratio),,,1.28,1.01,1.62,NA,NA,74,,NA
LR,,need to extract primary studies,NA,liu_2023a,ma_065,ma_m_248,fig10,liu_2023a_fig10,,other,one,PBDE,yes,,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,6,random effects model,NA,not reported,OR (odds ratio),,,1.04,0.82,1.3,NA,NA,45.1,,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_249,fig9,liu_2023a_fig9,women,PFAS,one,PFDA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,6,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.28,0.73,2.24,NA,NA,86.4,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_250,fig9,liu_2023a_fig9,women,PFAS,one,PFDoDA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.69,0.5,0.95,NA,NA,21.7,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_251,fig9,liu_2023a_fig9,women,PFAS,one,PFHpA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.15,0.77,1.71,NA,NA,25.8,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_252,fig9,liu_2023a_fig9,women,PFAS,one,PFHxS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,6,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.02,0.74,1.41,NA,NA,62.1,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_253,fig9,liu_2023a_fig9,women,PFAS,one,PFNA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,7,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.88,0.57,1.38,NA,NA,75.3,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_254,fig9,liu_2023a_fig9,women,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,11,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.1,0.77,1.57,NA,NA,82.5,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_255,fig9,liu_2023a_fig9,women,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,10,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.82,1.4,NA,NA,75.6,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_256,fig9,liu_2023a_fig9,women,PFAS,one,PFTrDA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.26,0.04,1.57,NA,NA,97.6,NA,NA
LR,,completed (primary studies not provided),NA,liu_2023a,ma_065,ma_m_257,fig9,liu_2023a_fig9,women,PFAS,one,PFUnDA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,4,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.99,0.61,1.61,NA,NA,71.5,NA,NA
LR,,need to extract primary studies,4 types of OCPs,xu_2023a,ma_066,ma_m_258,fig4,xu_2023a_fig4_OCPs_spermcount,,OCP,multiple,NA,yes,,sperm count,,reproductive disorders,,semen quality,,7,random effects model,NA,not reported,OR (odds ratio),,,1.31,1.19,1.44,NA,NA,96.9,,NA
LR,,need to extract primary studies,5 types of OCPs,xu_2023a,ma_066,ma_m_259,fig4,xu_2023a_fig4_OCPs_spermconcentration,,OCP,multiple,NA,yes,,sperm concentration,,reproductive disorders,,semen quality,,13,random effects model,NA,not reported,OR (odds ratio),,,1.34,1.1,1.63,NA,NA,95.4,,NA
LR,,need to extract primary studies,6 types of OCPs,xu_2023a,ma_066,ma_m_260,fig4,xu_2023a_fig4_OCPs_spermmorphology,,OCP,multiple,NA,yes,,sperm morphology,,reproductive disorders,,semen quality,,9,random effects model,NA,not reported,OR (odds ratio),,,1.42,1.02,1.99,NA,NA,97.5,,NA
LR,,need to extract primary studies,3 types of OCPs,xu_2023a,ma_066,ma_m_261,fig4,xu_2023a_fig4_OCPs_spermvolume,,OCP,multiple,NA,yes,,sperm volume,,reproductive disorders,,semen quality,,5,random effects model,NA,not reported,OR (odds ratio),,,1.79,1.15,2.79,NA,NA,99.5,,NA
LR,,need to extract primary studies,4 types of OCPs,xu_2023a,ma_066,ma_m_262,fig4,xu_2023a_fig4_OCPs_spermmotility,,OCP,multiple,NA,yes,,sperm motility,,reproductive disorders,,semen quality,,7,random effects model,NA,not reported,OR (odds ratio),,,1.87,1.16,3.01,NA,NA,98.2,,NA
LR,,need to extract primary studies,NA,xu_2023a,ma_066,ma_m_263,fig9,xu_2023a_fig4_DDE_spermcount,,OCP,one,DDE,yes,,sperm count,,reproductive disorders,,semen quality,,3,random effects model,NA,not reported,OR (odds ratio),,,1.01,0.98,1.04,NA,NA,4.3,,NA
LR,,need to extract primary studies,NA,xu_2023a,ma_066,ma_m_264,fig9,xu_2023a_fig4_DDE_spermconcentration,,OCP,one,DDE,yes,,sperm concentration,,reproductive disorders,,semen quality,,10,random effects model,NA,not reported,OR (odds ratio),,,1.05,0.98,1.13,NA,NA,49.2,,NA
LR,,need to extract primary studies,NA,xu_2023a,ma_066,ma_m_265,fig9,xu_2023a_fig4_DDE_spermmorphology,,OCP,one,DDE,yes,,sperm morphology,,reproductive disorders,,semen quality,,6,random effects model,NA,not reported,OR (odds ratio),,,1,0.97,1.03,NA,NA,0,,NA
LR,,need to extract primary studies,NA,xu_2023a,ma_066,ma_m_266,fig9,xu_2023a_fig4_DDE_spermvolume,,OCP,one,DDE,yes,,sperm volume,,reproductive disorders,,semen quality,,2,random effects model,NA,not reported,OR (odds ratio),,,1,0.99,1.01,NA,NA,0,,NA
LR,,need to extract primary studies,NA,xu_2023a,ma_066,ma_m_267,fig9,xu_2023a_fig4_DDE_spermmotility,,OCP,one,DDE,yes,,sperm motility,,reproductive disorders,,semen quality,,3,random effects model,NA,not reported,OR (odds ratio),,,1.06,0.77,1.46,NA,NA,77.8,,NA
LR,,need to extract primary studies,postnatal exposure,uldbjerg_2022,ma_067,ma_m_268,fig4B,uldbjerg_2022_fig4b,,OCP,multiple,NA,yes,,earlier age at menarche,,reproductive disorders,,pubertal timing,3,5,random effects model,NA,not reported,RR (risk ratio),,,1.09,0.99,1.19,NA,NA,39,0.0043,NA
,,,,vendl_2022,ma_068,ma_m_269,,,,,,,no,,,,,,,,,,,,,,,,,,,,,,
LR,,need to extract primary studies,measured maternal exposure to pesticides,wang_2021,ma_069,ma_m_270,fig2,wang_2021_fig2,,other,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,4,4,random effects model,NA,not reported,OR (odds ratio),,,1.13,0.83,1.54,NA,NA,61.9,,NA
LR,,need to extract primary studies,estimated maternal exposure to pesticides,wang_2021,ma_069,ma_m_271,fig3,wang_2021_fig3,,other,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,4,4,random effects model,NA,not reported,OR (odds ratio),,,1.88,1.1,3.2,NA,NA,85.8,,NA
LR,,need to extract primary studies,girls,lan_2023a,ma_070,ma_m_272,fig2B,lan_2023_fig2b_DDE,,OCP,one,DDE,yes,,pubertal timing,?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders","Pubertal timing. From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",4,4,random effects model,NA,not reported,relative risk,,,0.89,0.73,1.07,NA,NA,0,,NA
LR,,need to extract primary studies,girls,lan_2023a,ma_070,ma_m_273,fig2B,lan_2023_fig2b_HCB,,OCP,one,HCB,yes,,pubertal timing,?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders","Pubertal timing. From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",3,3,random effects model,NA,not reported,relative risk,,,0.63,0.49,0.79,NA,NA,0,,NA
LR,,need to extract primary studies,girls,lan_2023a,ma_070,ma_m_274,fig2B,lan_2023_fig2b_OCPs,,OCP,multiple,NA,yes,,pubertal timing,5A91,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Pubertal timing. From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",3,4,random effects model,NA,not reported,relative risk,,,0.84,0.67,1.06,NA,NA,44.5,,NA
LR,,need to extract primary studies,girls,lan_2023a,ma_070,ma_m_275,fig2B,lan_2023_fig2b_PFOA,children,PFAS,one,PFOA,yes,yes,pubertal timing,5A91,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",3,5,random effects model,NA,not reported,relative risk,NA,NA,0.59,0.35,1,NA,NA,52.5,NA,NA
LR,,need to extract primary studies,girls,lan_2023a,ma_070,ma_m_276,fig2B,lan_2023_fig2b_PFOS,children,PFAS,one,PFOS,yes,yes,pubertal timing,5A91,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",3,5,random effects model,NA,not reported,relative risk,NA,NA,0.57,0.44,0.75,NA,NA,0,NA,NA
LR,,need to extract primary studies,girls,lan_2023a,ma_070,ma_m_277,fig2B,lan_2023_fig2b_PFHxS,children,PFAS,one,PFHxS,yes,yes,pubertal timing,5A91,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",2,4,random effects model,NA,not reported,relative risk,NA,NA,0.68,0.53,0.88,NA,NA,28.5,NA,NA
LR,,need to extract primary studies,NA,cartagena_2023,ma_071,ma_m_278,figureS2,cartagena_2023_figS2,,OCP,one,DDE,yes,,sum of skinfolds,,body composition,,NA,2,2,NA,NA,inverse variance,? (regression coefficient) value,,,1.09,0.99,1.18,NA,NA,0,,NA
LR,,need to extract primary studies,NA,cartagena_2023,ma_071,ma_m_279,figS4,cartagena_2023_figS4,,PFAS,one,PFOA,yes,yes,trunk fat percent,5B80.1,Endocrine diseases,"Endocrine, nutritional or metabolic diseases",Localised adiposity,2,2,NA,NA,inverse variance,? (regression coefficient) value,linear,"""however, to account for the sampling selection probabilities, we conservatively constructed stratum-weighted linear regression models to account for the sampling scheme used for participant selection"" From Hartman, T. J., Calafat, A. M., Holmes, A. K., Marcus, M., Northstone, K., Flanders, W. D., ... & Taylor, E. V. (2017). Prenatal exposure to perfluoroalkyl substances and body fatness in girls. Childhood Obesity, 13(3), 222-230.",-0.28,-0.55,-0.01,NA,NA,0,NA,NA
LR,,need to extract primary studies,pesticide,wu_2023,ma_072,ma_m_280,fig3A,wu_2023_fig3A,,other,multiple,NA,yes,,risk of suicide deaths and suicide attempts,MB26.A,Suicidal ideation,"Mental or behavioural symptoms, signs or clinical findings",NA,15,15,random effects model,NA,not reported,OR (odds ratio),,,1.31,1.04,1.64,NA,NA,94.8,,NA
LR,,need to extract primary studies,pesticide,wu_2023,ma_072,ma_m_281,fig3C,wu_2023_fig3C,,other,multiple,NA,yes,,suicidal ideation,MB26.A,Suicidal ideation,"Mental or behavioural symptoms, signs or clinical findings",NA,5,5,random effects model,NA,not reported,OR (odds ratio),,,2.43,1.51,3.91,NA,NA,67.8,,NA
LR,,need to extract primary studies,overall estimates for other chemicals provided but not extracted,sirikul_2023,ma_073,ma_m_282,fig2,sirikul_2023_fig2,,OCP,multiple,NA,yes,,hypothyroidism,,metabolic diseases,,NA,7,56,random effects model,NA,inverse variance,aOR (adjusted odds ratio),,,1.23,1.14,1.33,NA,NA,43.4,,NA
,,,,kouiti_2023,ma_074,ma_m_283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR,,need to extract primary studies,table A8.1 is from Supplementary data 2,lin_2023,ma_075,ma_m_284,table A8.1,lin_2023_tabA8.1,,OCP,one,"p,p'-DDE",yes,,risk of preterm birth,,pregnancy disorders,,NA,1,3,random effects model,NA,not reported,? (regression coefficient) value,,,2.13,0.19,23.35,NA,NA,45.22,,NA
LR,,need to extract primary studies,table A8.2 is from Supplementary data 2,lin_2023,ma_075,ma_m_285,table A8.2,lin_2023_tabA8.2_DDE,,OCP,one,"p,p'-DDE",yes,,length of gestational age at birth,,pregnancy disorders,,NA,4,8,random effects model,NA,not reported,? (regression coefficient) value,,,-0.15,-0.61,0.3,NA,NA,72.17,,NA
LR,,need to extract primary studies,table A8.2 is from Supplementary data 2,lin_2023,ma_075,ma_m_286,table A8.2,lin_2023_tabA8.2_HCB,,OCP,one,HCB,yes,,length of gestational age at birth,,pregnancy disorders,,NA,4,5,random effects model,NA,not reported,? (regression coefficient) value,,,-0.15,-0.72,0.27,NA,NA,2.94,,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_287,fig1A1,liu_2023b_fig1A1,children and adults,PFAS,one,PFOA,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,34,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,2.11,1.23,3,NA,NA,87.9,3.52,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_288,fig1A2,liu_2023b_fig1A2,children and adults,PFAS,one,PFOA,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,27,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,1.4,0.61,2.19,NA,NA,78,2.12,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_289,fig1A3,liu_2023b_fig1A3,children and adults,PFAS,one,PFOA,yes,yes,high-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,34,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,0.16,-0.18,0.5,NA,NA,76.6,0.47,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_290,fig1A4,liu_2023b_fig1A4,children and adults,PFAS,one,PFOA,yes,yes,triacylglycerol,MA10.1,"Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system","Symptoms, signs or clinical findings, not elsewhere classified","Abnormal levels of other specified serum enzymes. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,29,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,1.26,0.08,2.43,NA,NA,59.6,3.77,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_291,fig1B1,liu_2023b_fig1B1,children and adults,PFAS,one,PFOS,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,25,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,2.55,1.48,3.61,NA,NA,90.9,4.56,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_292,fig1B2,liu_2023b_fig1B2,children and adults,PFAS,one,PFOS,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,20,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,1.94,0.92,2.96,NA,NA,92.6,3.99,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_293,fig1B3,liu_2023b_fig1B3,children and adults,PFAS,one,PFOS,yes,yes,high-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,22,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,0.33,-0.05,0.71,NA,NA,88.9,0.49,NA
LR,,need to extract primary studies,NA,liu_2023b,ma_076,ma_m_294,fig1B4,liu_2023b_fig1B4,children and adults,PFAS,one,PFOS,yes,yes,triacylglycerol,MA10.1,"Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system","Symptoms, signs or clinical findings, not elsewhere classified","Abnormal levels of other specified serum enzymes. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",,22,random effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,-0.99,-2.16,0.18,NA,NA,74.2,3.98,NA
LR,,need to extract primary studies,NA,shillemans_2023,ma_077,ma_m_295,fig1A,shillemans_2023_fig1A,teenagers ,PFAS,one,PFOA,yes,no,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",teenagers obesity,,9,random and fixed effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,-0.08,-0.15,-0.01,NA,NA,20.8,NA,NA
LR,,need to extract primary studies,NA,shillemans_2023,ma_077,ma_m_296,fig1B,shillemans_2023_fig1B,teenagers ,PFAS,one,PFNA,yes,no,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",teenagers obesity,,8,random and fixed effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,-0.06,-0.13,0.01,NA,NA,17.7,NA,NA
LR,,need to extract primary studies,NA,shillemans_2023,ma_077,ma_m_297,fig1C,shillemans_2023_fig1C,teenagers ,PFAS,one,PFHxS,yes,no,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",teenagers obesity,,8,random and fixed effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,0.02,-0.08,0.12,NA,NA,63.8,NA,NA
LR,,need to extract primary studies,NA,shillemans_2023,ma_077,ma_m_298,fig1D,shillemans_2023_fig1D,teenagers ,PFAS,one,PFOS,yes,no,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",teenagers obesity,,9,random and fixed effects model,NA,not reported,IQR increase (difference between 25th to 75th percentile),NA,NA,-0.04,-0.13,0.04,NA,NA,46.2,NA,NA
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_299,fig2,,children and adults,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,11,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.13,0.99,1.29,NA,NA,80.8,NA,NA
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_300,fig2,,children and adults,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,11,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.17,1.05,1.3,NA,NA,88,NA,NA
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_301,fig2,,children and adults,PFAS,one,PFHxS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,7,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.02,0.95,1.1,NA,NA,50.4,NA,NA
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_302,fig2,,children and adults,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.98,1.16,NA,NA,45.2,NA,NA
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_303,fig2,,children and adults,PFAS,one,PFDA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,7,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.96,0.85,1.08,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_304,tab3,,children and adults,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,4,random effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.24,-0.01,0.49,NA,NA,97.6,NA,<0.001
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_305,tab3,,children and adults,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,4,random effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.41,-0.11,0.93,NA,NA,99.4,NA,<0.001
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_306,tab3,,children and adults,PFAS,one,PFHxS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,2,random effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.18,0.12,0.23,NA,NA,0,NA,0.923
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_307,tab3,,children and adults,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,3,random effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.08,0.02,0.13,NA,NA,0,NA,<0.001
LR,,need to extract primary studies,NA,yang_2023,ma_078,ma_m_308,tab3,,children and adults,PFAS,one,PFDA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,2,random effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.21,-0.05,0.47,NA,NA,97.7,NA,0.651
LR,,need to extract primary studies,unstable sensitivity analysis,hirke_2023,ma_079,ma_m_309,tab3,,pregnant women,PFAS,one,PFOA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.2,1.04,1.39,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,hirke_2023,ma_079,ma_m_310,tab3,,pregnant women,PFAS,one,PFOS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.23,1.1,1.38,NA,NA,0,NA,NA
LR,,completed (primary studies not provided).,unstable sensitivity analysis,hirke_2023,ma_079,ma_m_311,tab3,,pregnant women,PFAS,one,PFHxS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,7,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.13,0.99,1.28,NA,NA,36,NA,NA
LR,,need to extract primary studies,unstable sensitivity analysis,hirke_2023,ma_079,ma_m_312,tab3,,pregnant women,PFAS,one,PFNA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.2,1.03,1.4,NA,NA,0,NA,NA
LR,,completed (primary studies not provided),NA,hirke_2023,ma_079,ma_m_313,tab3,,pregnant women,PFAS,one,PFDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,5,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.09,0.91,1.3,NA,NA,1,NA,NA
LR,,completed (primary studies not provided),NA,hirke_2023,ma_079,ma_m_314,tab3,,pregnant women,PFAS,one,PFHpA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,0.96,0.83,1.11,NA,NA,39,NA,NA
LR,,completed (primary studies not provided),NA,hirke_2023,ma_079,ma_m_315,tab3,,pregnant women,PFAS,one,PFUnDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,0.89,0.72,0.94,NA,NA,0,NA,NA
LR,,need to extract primary studies,unstable sensitivity analysis,hirke_2023,ma_079,ma_m_316,tab3,,pregnant women,PFAS,one,PFOA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,4,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.18,1.01,1.39,NA,NA,35,NA,NA
LR,,completed (primary studies not provided),unstable sensitivity analysis,hirke_2023,ma_079,ma_m_317,tab3,,pregnant women,PFAS,one,PFOS,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,4,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.14,0.98,1.33,NA,NA,29,NA,NA
LR,,completed (primary studies not provided),NA,hirke_2023,ma_079,ma_m_318,tab3,,pregnant women,PFAS,one,PFNA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,3,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.05,0.85,1.29,NA,NA,44,NA,NA
LR,,completed (primary studies not provided),NA,hirke_2023,ma_079,ma_m_319,tab3,,pregnant women,PFAS,one,PFDA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,3,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,0.88,0.7,1.11,NA,NA,0,NA,NA
LR,,need to extract primary studies,unstable sensitivity analysis,hirke_2023,ma_079,ma_m_320,tab3,,pregnant women,PFAS,one,PFHxS,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",preeclampsia,4,,NA,"the study states that ""If the I2 ? 50, indicated significant inconsistency, a random-effect model was selected (Julian Higgins et al., 2021).""",not reported,OR (odds ratio),NA,NA,1.15,1.02,1.29,NA,NA,49,NA,NA
LR,,need to extract primary studies,NA,pan_2023,ma_080,ma_m_321,fig2,,,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,8,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.11,1.04,1.19,NA,NA,22.4,NA,NA
LR,,need to extract primary studies,NA,pan_2023,ma_080,ma_m_322,fig2,,,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,13,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.12,1.02,1.23,NA,NA,75.4,NA,NA
LR,,need to extract primary studies,NA,pan_2023,ma_080,ma_m_323,fig2,,,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,12,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.19,1.06,1.34,NA,NA,87.8,NA,NA
LR,,need to extract primary studies,NA,pan_2023,ma_080,ma_m_324,fig3,,,PFAS,one,PFDA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,3,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.96,0.85,1.08,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,pan_2023,ma_080,ma_m_325,fig3,,,PFAS,one,PFHxS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,9,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.03,1,1.06,NA,NA,57,NA,NA
LR,,need to extract primary studies,NA,pan_2023,ma_080,ma_m_326,fig3,,,PFAS,one,PFUnDA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,3,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.95,0.9,1.01,NA,NA,0,NA,NA
LR,,need to extract primary studies,male,pan_2023,ma_080,ma_m_327,fig4,,,PFAS,one,PFHxS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,4,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.04,0.94,1.15,NA,NA,57.5,NA,NA
LR,,need to extract primary studies,female,pan_2023,ma_080,ma_m_328,fig4,,,PFAS,one,PFHxS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,4,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.08,0.94,1.23,NA,NA,62.9,NA,NA
LR,,need to extract primary studies,male,pan_2023,ma_080,ma_m_329,fig4,,,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,4,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.12,1.03,1.22,NA,NA,0,NA,NA
LR,,need to extract primary studies,female,pan_2023,ma_080,ma_m_330,fig4,,,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,4,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.14,0.93,1.41,NA,NA,76.2,NA,NA
LR,,need to extract primary studies,male,pan_2023,ma_080,ma_m_331,fig5,,,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,6,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.12,1.01,1.25,NA,NA,29.7,NA,NA
LR,,need to extract primary studies,female,pan_2023,ma_080,ma_m_332,fig5,,,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,6,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.22,0.99,1.5,NA,NA,72.4,NA,NA
LR,,need to extract primary studies,male,pan_2023,ma_080,ma_m_333,fig5,,,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,6,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.12,1,1.25,NA,NA,36.6,NA,NA
LR,,need to extract primary studies,female,pan_2023,ma_080,ma_m_334,fig5,,,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",,6,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.36,0.94,1.97,NA,NA,91.9,NA,NA
LR,,need to extract primary studies,NA,crawford_2023,ma_081,ma_m_335,,,,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",13,,random effects model,NA,not reported,difference in loge (antibody concentration) per doubling of PFAS,NA,NA,-0.0558,-0.1002,-0.0113,NA,NA,63,NA,NA
LR,,need to extract primary studies,NA,crawford_2023,ma_081,ma_m_336,,,,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",13,,random effects model,NA,not reported,difference in loge (antibody concentration) per doubling of PFAS,NA,NA,-0.0616,-0.1122,-0.011,NA,NA,53,NA,NA
LR,,need to extract primary studies,NA,crawford_2023,ma_081,ma_m_337,,,,PFAS,one,PFHsX,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",10,,random effects model,NA,not reported,difference in loge (antibody concentration) per doubling of PFAS,NA,NA,-0.0326,-0.0645,-0.0007,NA,NA,48,NA,NA
LR,,need to extract primary studies,NA,crawford_2023,ma_081,ma_m_338,,,,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",10,,random effects model,NA,not reported,difference in loge (antibody concentration) per doubling of PFAS,NA,NA,-0.0425,-0.0948,0.0098,NA,NA,67,NA,NA
LR,,need to extract primary studies,NA,crawford_2023,ma_081,ma_m_339,,,,PFAS,one,PFDA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,"Essential hypertension, unspecified",7,,random effects model,NA,not reported,difference in loge (antibody concentration) per doubling of PFAS,NA,NA,-0.0658,-0.1329,0.0013,NA,NA,75,NA,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_340,fig2,,,OCP,one,DDE,yes,,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases",also classified as kidney disease or gout and joint disorders or cardiovascular risk factors,3,3,random effects model,NA,not reported,OR (odds ratio),,,3.66,1.77,7.55,NA,NA,80,,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_341,fig2,,,OCP,one,DDT,yes,,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases",also classified as kidney disease or gout and joint disorders or cardiovascular risk factors,3,3,random effects model,NA,not reported,OR (odds ratio),,,2.31,1.27,4.2,NA,NA,74,,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_342,fig3,,,PCBs,multiple,NA,yes,,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases",also classified as kidney disease or gout and joint disorders or cardiovascular risk factors,3,3,random effects model,NA,not reported,OR (odds ratio),,,2.57,1.37,4.81,NA,NA,0,,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_343,fig4,,,PFAS,one,PFDA,yes,no,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Other specified inborn errors of purine, pyrimidine or nucleotide metabolism. Also classified as kidney disease or gout and joint disorders or cardiovascular risk factors",5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.06,0.96,1.17,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_344,fig4,,,PFAS,one,PFHxS,yes,no,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Other specified inborn errors of purine, pyrimidine or nucleotide metabolism. Also classified as kidney disease or gout and joint disorders or cardiovascular risk factors",5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.09,0.85,1.39,NA,NA,70,NA,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_345,fig5,,,PFAS,one,PFNA,yes,no,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Other specified inborn errors of purine, pyrimidine or nucleotide metabolism. Also classified as kidney disease or gout and joint disorders or cardiovascular risk factors",5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.26,1.07,1.47,NA,NA,33,NA,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_346,fig5,,,PFAS,one,PFOA,yes,no,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Other specified inborn errors of purine, pyrimidine or nucleotide metabolism. Also classified as kidney disease or gout and joint disorders or cardiovascular risk factors",6,6,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.44,1.16,1.79,NA,NA,60,NA,NA
LR,,need to extract primary studies,NA,yipei_2023,ma_082,ma_m_347,fig5,,,PFAS,one,PFOS,yes,no,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Other specified inborn errors of purine, pyrimidine or nucleotide metabolism. Also classified as kidney disease or gout and joint disorders or cardiovascular risk factors",6,6,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.23,1.01,1.5,NA,NA,58,NA,NA
LR,,need to extract primary studies,NA,lan_2023,ma_083,ma_m_348,fig3A,,children,PFAS,one,PFOA,yes,no,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,18,fixed effects model,NA,not reported,Adjusted ? (regression coefficient),linear,"""Binary outcomes were analyzed using logistic regression models, and continuous birth weight was analyzed using linear regression."" From Darrow LA, Stein CR, Steenland K (2013) Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005-2010. Environ Health Persp 121:1207–1213",-58.62,-85.23,-32.01,NA,NA,15.6,NA,NA
LR,,need to extract primary studies,NA,lan_2023,ma_083,ma_m_349,fig3B,,children,PFAS,one,PFOS,yes,no,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,,17,fixed effects model,NA,not reported,Adjusted ? (regression coefficient),linear,"""Binary outcomes were analyzed using logistic regression models, and continuous birth weight was analyzed using linear regression."" From Darrow LA, Stein CR, Steenland K (2013) Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005-2010. Environ Health Persp 121:1207–1213",-54.75,-84.48,-25.02,NA,NA,44,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_350,fig2A,,men,PFAS,one,PFOA,yes,yes,testosterone,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,21,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Estimated coefficient (?) with 95% CI of natural log-transformed testosterone (nmol/L) per each 1 (ng/mL) increase in PFAS levels in multivariate linear regression models."" From Zhou, Y., Hu, L. W., Qian, Z. M., Chang, J. J., King, C., Paul, G., ... & Dong, G. H. (2016). Association of perfluoroalkyl substances exposure with reproductive hormone levels in adolescents: by sex status. Environment international, 94, 189-195.",-0.04,-0.08,0,NA,NA,50.8,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_351,fig2B,,men,PFAS,one,PFOA,yes,yes,FSH,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",0.02,-0.01,0.05,NA,NA,48.9,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_352,fig2C,,men,PFAS,one,PFOA,yes,yes,LH,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",0,-0.02,0.03,NA,NA,3,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_353,fig2D,,men,PFAS,one,PFOA,yes,yes,estradiol,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,9,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Estimated coefficient (?) with 95%CI of natural log-transformed estradiol (pmol/L) per each 1 (ng/mL) increase in PFAS levels in multivariate linear regression models."" From Zhou, Y., Hu, L. W., Qian, Z. M., Chang, J. J., King, C., Paul, G., ... & Dong, G. H. (2016). Association of perfluoroalkyl substances exposure with reproductive hormone levels in adolescents: by sex status. Environment international, 94, 189-195.",0,-0.02,0.01,NA,NA,1.5,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_354,fig2E,,men,PFAS,one,PFOA,yes,yes,FAI,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",0,-0.02,0.02,NA,NA,32.4,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_355,fig2F,,men,PFAS,one,PFOA,yes,yes,inhibin,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",0,-0.03,0.02,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_356,fig2G,,men,PFAS,one,PFOA,yes,yes,SHBG,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,9,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",-0.02,-0.04,0,NA,NA,32.6,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_357,fig2H,,men,PFAS,one,PFOA,yes,yes,T/LH,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",-0.01,-0.04,0.01,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_358,fig3A,,men,PFAS,one,PFNA,yes,yes,testosterone,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,13,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",-0.05,-0.09,-0.02,NA,NA,46.4,NA,NA
LR,,need to extract primary studies,NA,sang_2024,ma_084,ma_m_359,fig3B,,men,PFAS,one,PFNA,yes,yes,estradiol,5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""Analysis for association between quartile group and hormone levels or semen variables was conducted using univariate regression analysis, adjusted for the abovementioned confounders."" From Joensen, U. N., Bossi, R., Leffers, H., Jensen, A. A., Skakkebæk, N. E., & Jørgensen, N. (2009). Do perfluoroalkyl compounds impair human semen quality?. Environmental health perspectives, 117(6), 923-927.",0.01,-0.07,0.08,NA,NA,37.4,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_360,,,,PFAS,one,PFOA,yes,yes,Full Scale Intelligence Quotient (FSIQ),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,9,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""We determined whether a dose response relationship was present using the median value of each tertile as a continuous variable in multiple linear regression analyses between PFAS at either gestation, 3 years, or 8 years and WISC-IV outcomes at age 8 years"" From Vuong, A. M., Yolton, K., Xie, C., Dietrich, K. N., Braun, J. M., Webster, G. M., ... & Chen, A. (2019). Prenatal and childhood exposure to poly-and perfluoroalkyl substances (PFAS) and cognitive development in children at age 8 years. Environmental research, 172, 242-248.",0.04,-0.49,0.57,NA,NA,33.9,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_361,,,,PFAS,one,PFOS,yes,yes,Full Scale Intelligence Quotient (FSIQ),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,9,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""We determined whether a dose response relationship was present using the median value of each tertile as a continuous variable in multiple linear regression analyses between PFAS at either gestation, 3 years, or 8 years and WISC-IV outcomes at age 8 years"" From Vuong, A. M., Yolton, K., Xie, C., Dietrich, K. N., Braun, J. M., Webster, G. M., ... & Chen, A. (2019). Prenatal and childhood exposure to poly-and perfluoroalkyl substances (PFAS) and cognitive development in children at age 8 years. Environmental research, 172, 242-248.",-0.37,-0.89,0.16,NA,NA,46.4,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_362,,,,PFAS,one,PFHxS,yes,yes,Full Scale Intelligence Quotient (FSIQ),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,9,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""We determined whether a dose response relationship was present using the median value of each tertile as a continuous variable in multiple linear regression analyses between PFAS at either gestation, 3 years, or 8 years and WISC-IV outcomes at age 8 years"" From Vuong, A. M., Yolton, K., Xie, C., Dietrich, K. N., Braun, J. M., Webster, G. M., ... & Chen, A. (2019). Prenatal and childhood exposure to poly-and perfluoroalkyl substances (PFAS) and cognitive development in children at age 8 years. Environmental research, 172, 242-248.",-0.03,-0.46,0.39,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_363,,,,PFAS,one,PFNA,yes,yes,Full Scale Intelligence Quotient (FSIQ),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,8,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""We determined whether a dose response relationship was present using the median value of each tertile as a continuous variable in multiple linear regression analyses between PFAS at either gestation, 3 years, or 8 years and WISC-IV outcomes at age 8 years"" From Vuong, A. M., Yolton, K., Xie, C., Dietrich, K. N., Braun, J. M., Webster, G. M., ... & Chen, A. (2019). Prenatal and childhood exposure to poly-and perfluoroalkyl substances (PFAS) and cognitive development in children at age 8 years. Environmental research, 172, 242-248.",0.13,-0.89,1.15,NA,NA,54.5,NA,NA
LR,,need to extract primary studies,boys,liu_2024,ma_085,ma_m_364,,,,PFAS,one,PFOS,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",-1.56,-2.96,-0.17,NA,NA,0,NA,NA
LR,,need to extract primary studies,girls,liu_2024,ma_085,ma_m_365,,,,PFAS,one,PFOS,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",1.56,0.06,3.06,NA,NA,0,NA,NA
LR,,need to extract primary studies,boys,liu_2024,ma_085,ma_m_366,,,,PFAS,one,PFOA,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",-1.87,-3.29,-0.46,NA,NA,0,NA,NA
LR,,need to extract primary studies,girls,liu_2024,ma_085,ma_m_367,,,,PFAS,one,PFOA,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",1.36,-0.1,2.82,NA,NA,0,NA,NA
LR,,need to extract primary studies,boys,liu_2024,ma_085,ma_m_368,,,,PFAS,one,PFHxS,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",-2.02,-3.23,-0.81,NA,NA,0,NA,NA
LR,,need to extract primary studies,girls,liu_2024,ma_085,ma_m_369,,,,PFAS,one,PFHxS,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",-0.03,-1.16,1.1,NA,NA,0,NA,NA
LR,,need to extract primary studies,boys,liu_2024,ma_085,ma_m_370,,,,PFAS,one,PFNA,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,2,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",0.44,-2.82,3.69,NA,NA,0,NA,NA
LR,,need to extract primary studies,girls,liu_2024,ma_085,ma_m_371,,,,PFAS,one,PFNA,yes,yes,Performance IQ (Performance Intelligence Quotient),6A00.Z ,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,2,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""we fit multivariate linear regression models between each prenatal PFAS and each IQ score measured at each year."" From Wang, Y., Rogan, W. J., Chen, H. Y., Chen, P. C., Su, P. H., Chen, H. Y., & Wang, S. L. (2015). Prenatal exposure to perfluroalkyl substances and children's IQ: The Taiwan maternal and infant cohort study. International journal of hygiene and environmental health, 218(7), 639-644.",0.59,-2.42,3.6,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_372,,,,PFAS,one,PFOS,yes,yes,Behavioral Regulation Index (BRI),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Multivariable linear regression analyses using robust standard errors were used to examine the associations between the levels of seven PFAS and the standardized BRIEF and TEACh-5 test scores, unadjusted and adjusted for potential confounders."" From Bach, C. C., Liew, Z., Matthiesen, N. B., Henriksen, T. B., Bech, B. H., Nøhr, E. A., ... & Olsen, J. (2022). In utero exposure to perfluoroalkyl and polyfluoroalkyl substances and attention and executive function in the offspring: A study in the Danish National Birth Cohort. Environmental Research, 212, 113262.",2.48,1.06,3.89,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_373,,,,PFAS,one,PFOA,yes,yes,Behavioral Regulation Index (BRI),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Multivariable linear regression analyses using robust standard errors were used to examine the associations between the levels of seven PFAS and the standardized BRIEF and TEACh-5 test scores, unadjusted and adjusted for potential confounders."" From Bach, C. C., Liew, Z., Matthiesen, N. B., Henriksen, T. B., Bech, B. H., Nøhr, E. A., ... & Olsen, J. (2022). In utero exposure to perfluoroalkyl and polyfluoroalkyl substances and attention and executive function in the offspring: A study in the Danish National Birth Cohort. Environmental Research, 212, 113262.",2.12,0.75,3.49,NA,NA,36.6,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_374,,,,PFAS,one,PFHxS,yes,yes,Behavioral Regulation Index (BRI),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Multivariable linear regression analyses using robust standard errors were used to examine the associations between the levels of seven PFAS and the standardized BRIEF and TEACh-5 test scores, unadjusted and adjusted for potential confounders."" From Bach, C. C., Liew, Z., Matthiesen, N. B., Henriksen, T. B., Bech, B. H., Nøhr, E. A., ... & Olsen, J. (2022). In utero exposure to perfluoroalkyl and polyfluoroalkyl substances and attention and executive function in the offspring: A study in the Danish National Birth Cohort. Environmental Research, 212, 113262.",1.06,0.02,2.09,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_375,,,,PFAS,one,PFNA,yes,yes,Behavioral Regulation Index (BRI),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Multivariable linear regression analyses using robust standard errors were used to examine the associations between the levels of seven PFAS and the standardized BRIEF and TEACh-5 test scores, unadjusted and adjusted for potential confounders."" From Bach, C. C., Liew, Z., Matthiesen, N. B., Henriksen, T. B., Bech, B. H., Nøhr, E. A., ... & Olsen, J. (2022). In utero exposure to perfluoroalkyl and polyfluoroalkyl substances and attention and executive function in the offspring: A study in the Danish National Birth Cohort. Environmental Research, 212, 113262.",1.79,0.37,3.2,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_376,,,,PFAS,one,PFOS,yes,,Total difficulties,?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,logistic,"""Odds ratios (ORs) were estimated using logistic regression analysis with continuous exposure variables and dichotomized outcome variables for both SDQ and hyperactivity score. As previously used for SDQ analysis on Greenlandic children53, normal and borderline were combined and compared to abnormal."" From Kornvig, S., Wielsøe, M., Long, M., & Bonefeld-Jørgensen, E. C. (2021). Prenatal exposure to persistent organic pollutants and metals and problematic child behavior at 3–5 years of age: a Greenlandic cohort study. Scientific reports, 11(1), 22182.",0.16,-0.08,0.4,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_377,,,,PFAS,one,PFOA,yes,,Total difficulties,?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,3,random and fixed effects model,NA,not reported,? (regression coefficient) value,logistic,"""Odds ratios (ORs) were estimated using logistic regression analysis with continuous exposure variables and dichotomized outcome variables for both SDQ and hyperactivity score. As previously used for SDQ analysis on Greenlandic children53, normal and borderline were combined and compared to abnormal."" From Kornvig, S., Wielsøe, M., Long, M., & Bonefeld-Jørgensen, E. C. (2021). Prenatal exposure to persistent organic pollutants and metals and problematic child behavior at 3–5 years of age: a Greenlandic cohort study. Scientific reports, 11(1), 22182.",-0.07,-0.49,0.35,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_378,,,,PFAS,one,PFHxS,yes,,Total difficulties,?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,2,random and fixed effects model,NA,not reported,? (regression coefficient) value,logistic,"""Odds ratios (ORs) were estimated using logistic regression analysis with continuous exposure variables and dichotomized outcome variables for both SDQ and hyperactivity score. As previously used for SDQ analysis on Greenlandic children53, normal and borderline were combined and compared to abnormal."" From Kornvig, S., Wielsøe, M., Long, M., & Bonefeld-Jørgensen, E. C. (2021). Prenatal exposure to persistent organic pollutants and metals and problematic child behavior at 3–5 years of age: a Greenlandic cohort study. Scientific reports, 11(1), 22182.",0.05,-0.61,0.72,NA,NA,69.1,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_085,ma_m_379,,,,PFAS,one,PFNA,yes,,Total difficulties,?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,,2,random and fixed effects model,NA,not reported,? (regression coefficient) value,logistic,"""Odds ratios (ORs) were estimated using logistic regression analysis with continuous exposure variables and dichotomized outcome variables for both SDQ and hyperactivity score. As previously used for SDQ analysis on Greenlandic children53, normal and borderline were combined and compared to abnormal."" From Kornvig, S., Wielsøe, M., Long, M., & Bonefeld-Jørgensen, E. C. (2021). Prenatal exposure to persistent organic pollutants and metals and problematic child behavior at 3–5 years of age: a Greenlandic cohort study. Scientific reports, 11(1), 22182.",0.18,-0.61,0.97,NA,NA,55.6,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_380,fig2,,children,PFAS,one,PFOA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,18,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0015,-0.0112,0.0081,NA,NA,0.58,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_381,fig2,,children,PFAS,one,PFOS,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,18,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0002,-0.0014,0.001,NA,NA,0.57,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_382,fig2,,children,PFAS,one,PFHxS,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,11,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0,-0.007,0.0069,NA,NA,0,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_383,fig2,,children,PFAS,one,PFNA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,11,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0002,-0.0034,0.0029,NA,NA,0.21,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_384,fig2,,children,PFAS,one,PFDA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,7,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0008,-0.0045,0.0029,NA,NA,0.03,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_385,fig2,,children,PFAS,one,PFUnDA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,7,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0016,-0.0048,0.0017,NA,NA,0,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_386,fig2,,children,PFAS,one,PFDoDA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,3,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0154,-0.0306,0.0614,NA,NA,0.5,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_387,fig2,,children,PFAS,one,PFBS,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,3,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0011,-0.0073,0.0096,NA,NA,0.52,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_388,fig2,,children,PFAS,one,PFOA,yes,no,risk of overweight,5B80.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,9,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0084,-0.0003,0.0171,NA,NA,0.02,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_389,fig2,,children,PFAS,one,PFOS,yes,no,risk of overweight,5B80.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,9,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0007,-0.0012,0.0026,NA,NA,0.19,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_390,fig2,,children,PFAS,one,PFHxS,yes,no,risk of overweight,5B80.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,6,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0035,-0.0235,0.0166,NA,NA,0.41,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_391,fig2,,children,PFAS,one,PFNA,yes,no,risk of overweight,5B80.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,6,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.025,-0.0116,0.0616,NA,NA,0.02,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_392,fig2,,children,PFAS,one,PFOA,yes,yes,waist circumference,?,body metrics,"Endocrine, nutritional or metabolic diseases",childhood obesity,,8,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0,-0.0001,0,NA,NA,0,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_393,fig2,,children,PFAS,one,PFOS,yes,yes,waist circumference,?,body metrics,"Endocrine, nutritional or metabolic diseases",childhood obesity,,8,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0,0,0.0001,NA,NA,0,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_394,fig2,,children,PFAS,one,PFHxS,yes,yes,waist circumference,?,body metrics,"Endocrine, nutritional or metabolic diseases",childhood obesity,,8,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0001,-0.0001,0.0003,NA,NA,0,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_395,fig2,,children,PFAS,one,PFNA,yes,yes,waist circumference,?,body metrics,"Endocrine, nutritional or metabolic diseases",childhood obesity,,8,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0004,-0.0006,0.0015,NA,NA,0.16,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_396,fig2,,children,PFAS,one,PFDA,yes,yes,waist circumference,?,body metrics,"Endocrine, nutritional or metabolic diseases",childhood obesity,,4,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0003,-0.0002,0.0008,NA,NA,0,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_397,fig2,,children,PFAS,one,PFUnDA,yes,yes,waist circumference,?,body metrics,"Endocrine, nutritional or metabolic diseases",childhood obesity,,4,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0005,-0.001,0.002,NA,NA,0.67,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_398,fig2,,children,PFAS,one,PFOA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,8,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0525,-0.1039,-0.0012,NA,NA,0.84,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_399,fig2,,children,PFAS,one,PFOS,yes,yes,body mass index (BMI),5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,8,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0166,-0.0283,-0.0049,NA,NA,0.82,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_400,fig2,,children,PFAS,one,PFHxS,yes,yes,body mass index (BMI),5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,6,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0247,-0.0814,0.032,NA,NA,0.35,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_401,fig2,,children,PFAS,one,PFNA,yes,yes,body mass index (BMI),5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,6,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.2162,-0.4883,0.0558,NA,NA,0.81,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_402,fig2,,children,PFAS,one,PFOA,yes,no,risk of overweight,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,4,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,-0.0101,-0.0497,0.0295,NA,NA,0.84,NA,NA
LR,,need to extract primary studies,It also provides subcategories F/M,frigerio_2023,ma_086,ma_m_403,fig2,,children,PFAS,one,PFOS,yes,no,risk of overweight,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",childhood obesity,,4,random effects model,NA,inverse variance,SMD (standardized mean difference),NA,NA,0.0016,-0.0061,0.0113,NA,NA,0.78,NA,NA
LR,,need to extract primary studies,NA,dunder_2023,ma_087,ma_m_404,fig4,,,PFAS,one,PFOA,yes,no,incident CVD (cardiovascular disease),BA01,Diseases of the myocardium or cardiac chambers,Diseases of the circulatory system,NA,,5,random effects model,NA,inverse variance,RR (risk ratio),NA,NA,0.8,0.66,0.64,NA,NA,0,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_405,tab2,,,PFAS,multiple,PFAS,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),229,229,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.03,0.95,1.1,NA,NA,87.8,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_406,tab2,,,PFAS,one,PFOA,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),85,85,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.99,1.17,NA,NA,96.7,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_407,fig2,,,PFAS,one,PFOS,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),27,51,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.12,1,1.25,NA,NA,98.6,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_408,tab2,,,PFAS,one,PFNA,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),,36,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.98,0.84,1.15,NA,NA,99.4,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_409,tab2,,,PFAS,one,PFHxS,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),,35,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.95,0.69,1.33,NA,NA,99.9,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_410,tab2,,,PFAS,one,PFDA,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),,11,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.94,0.6,1.47,NA,NA,81.9,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_411,tab2,,,PFAS,one,PFUnDA,yes,no,risk of total cancer,,Malignant neoplasms,Neoplasms,it includes many different type of cancer (see tab1),,11,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.84,0.56,1.27,NA,NA,80,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_412,tab2,,,PFAS,multiple,PFAS,yes,no,gastointestinal tract cancer (GIC),,Malignant neoplasms,Neoplasms,"it includes colorectal cancer,  liver cancer, pancreatic cancer",,18,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.8,0.65,1,NA,NA,63.4,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_413,tab2,,,PFAS,one,PFOA,yes,no,gastointestinal tract cancer (GIC),,Malignant neoplasms,Neoplasms,"it includes colorectal cancer,  liver cancer, pancreatic cancer",,10,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.78,0.64,0.95,NA,NA,1,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_414,tab2,,,PFAS,one,PFOS,yes,no,gastointestinal tract cancer (GIC),,Malignant neoplasms,Neoplasms,"it includes colorectal cancer,  liver cancer, pancreatic cancer",,5,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.75,0.38,1.48,NA,NA,88.3,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_415,tab2,,,PFAS,multiple,PFAS,yes,no,genitourinary cancer,,Malignant neoplasms,Neoplasms,it includes pancreatic cancer; kidney cancer; prostate cancer; testicular cancer; cervical cancer; ovarian cancer; uterine cancer,,86,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.28,1.21,1.36,NA,NA,93.7,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_416,tab2,,,PFAS,one,PFOA,yes,no,genitourinary cancer,,Malignant neoplasms,Neoplasms,it includes pancreatic cancer; kidney cancer; prostate cancer; testicular cancer; cervical cancer; ovarian cancer; uterine cancer,,33,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.14,0.95,1.37,NA,NA,81.2,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_417,tab2,,,PFAS,one,PFOS,yes,no,genitourinary cancer,,Malignant neoplasms,Neoplasms,it includes pancreatic cancer; kidney cancer; prostate cancer; testicular cancer; cervical cancer; ovarian cancer; uterine cancer,,20,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.26,0.98,1.61,NA,NA,91.4,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_418,tab2,,,PFAS,one,PFNA,yes,no,genitourinary cancer,,Malignant neoplasms,Neoplasms,it includes pancreatic cancer; kidney cancer; prostate cancer; testicular cancer; cervical cancer; ovarian cancer; uterine cancer,,14,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.16,0.91,1.47,NA,NA,76.9,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_419,tab2,,,PFAS,one,PFHxS,yes,no,genitourinary cancer,,Malignant neoplasms,Neoplasms,it includes pancreatic cancer; kidney cancer; prostate cancer; testicular cancer; cervical cancer; ovarian cancer; uterine cancer,,14,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.18,0.93,1.48,NA,NA,80.3,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_420,tab2,,,PFAS,one,PFDA,yes,no,genitourinary cancer,,Malignant neoplasms,Neoplasms,it includes pancreatic cancer; kidney cancer; prostate cancer; testicular cancer; cervical cancer; ovarian cancer; uterine cancer,,4,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.45,1.04,2.02,NA,NA,0,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_421,tab2,,,PFAS,multiple,PFAS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,60,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.04,0.88,1.23,NA,NA,99.9,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_422,tab2,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,14,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.03,0.72,1.47,NA,NA,93.4,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_423,tab2,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,13,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.08,0.82,1.41,NA,NA,86.3,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_424,tab2,,,PFAS,one,PFNA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,11,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.94,0.77,1.16,NA,NA,67.6,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_425,tab2,,,PFAS,one,PFHxS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,11,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.44,2.63,NA,NA,98.9,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_426,tab2,,,PFAS,one,PFDA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,6,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.14,0.62,2.1,NA,NA,81.7,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_427,tab2,,,PFAS,one,PFUnDA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,5,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.99,0.61,1.61,NA,NA,71.4,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_428,tab2,,,PFAS,multiple,PFAS,yes,no,thyroid cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,25,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.59,0.45,0.77,NA,NA,87.3,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_429,tab2,,,PFAS,one,PFOA,yes,no,thyroid cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,8,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.81,0.52,1.27,NA,NA,73.9,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_430,tab2,,,PFAS,one,PFOS,yes,no,thyroid cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,5,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.06,0.69,1.61,NA,NA,71.7,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_431,tab2,,,PFAS,one,PFNA,yes,no,thyroid cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,5,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.64,0.36,1.13,NA,NA,85.7,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_432,tab2,,,PFAS,one,PFHxS,yes,no,thyroid cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,4,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.29,0.07,1.23,NA,NA,95.5,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_433,tab2,,,PFAS,multiple,PFAS,yes,no,hematologic cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,14,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.05,0.83,1.34,NA,NA,37.7,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_434,tab2,,,PFAS,multiple,PFAS,yes,no,lung cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,12,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.41,0.93,2.15,NA,NA,43.6,NA,NA
LR,,need to extract primary studies,We do not have info on the primary studies contributing to this estimate,yang_2024,ma_088,ma_m_435,tab2,,,PFAS,multiple,PFAS,yes,no,skin cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,14,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.19,0.89,1.58,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,yang_2024,ma_088,ma_m_436,fig3A,,,PFAS,one,PFDA,yes,no,risk of total cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",10,10,random and fixed effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.43,-0.01,0.87,NA,NA,97.5,NA,NA
LR,,need to extract primary studies,NA,yang_2024,ma_088,ma_m_437,fig3B,,,PFAS,one,PFOA,yes,no,risk of total cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",6,6,random and fixed effects model,NA,not reported,SMD (standardized mean difference),NA,NA,0.41,0.05,0.76,NA,NA,96.3,NA,NA
LR,,need to extract primary studies,NA,cong_2023,ma_089,ma_m_438,fig3,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",11,11,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.84,1.38,NA,NA,85.9,NA,NA
LR,,need to extract primary studies,NA,cong_2023,ma_089,ma_m_439,fig3,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,9,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,1.01,0.95,1.08,NA,NA,65.7,NA,NA
LR,,need to extract primary studies,NA,cong_2023,ma_089,ma_m_440,fig3,,,PFAS,one,PFNA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,7,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.89,0.67,1.19,NA,NA,74.4,NA,NA
LR,,need to extract primary studies,NA,cong_2023,ma_089,ma_m_441,fig3,,,PFAS,one,PFHxS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",,7,random and fixed effects model,NA,not reported,OR (odds ratio),NA,NA,0.9,0.72,1.13,NA,NA,74,NA,NA
LR,,need to extract primary studies,NA,cong_2023,ma_089,ma_m_442,fig2,,,OCP,one,TCDD,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",6,6,random and fixed effects model,NA,not reported,OR (odds ratio),,,1,0.89,1.12,NA,NA,39.3,,NA
LR,,need to extract primary studies,NA,xiao_2023,ma_090,ma_m_443,fig2,,,PFAS,one,PFOS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,NA,13,14,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.31,1.14,1.51,NA,NA,94.6,NA,NA
LR,,need to extract primary studies,NA,xiao_2023,ma_090,ma_m_444,fig2,,,PFAS,one,PFOA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,NA,14,15,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.16,1.07,1.26,NA,NA,88.4,NA,NA
LR,,need to extract primary studies,NA,xiao_2023,ma_090,ma_m_445,fig2,,,PFAS,one,PFNA,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,NA,9,10,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.08,0.99,1.17,NA,NA,56.8,NA,NA
LR,,need to extract primary studies,NA,xiao_2023,ma_090,ma_m_446,fig2,,,PFAS,one,PFHxS,yes,no,hypertension,BA00.Z,Hypertensive diseases,Diseases of the circulatory system,NA,10,11,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.04,1,1.09,NA,NA,60.6,NA,NA
LR,,completed (primary studies not provided),female,li_2024,ma_091,ma_m_447,tab2,,,PFAS,one,PFOA,yes,yes,E2 (estradiol),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",6,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Hence, we utilized multiple linear regressions to calculate the regression coefficient (?) and 95% confidence interval (CI) between each pair of PFAS and estrogen, adjusting for potential confounders (detailed information below)."" From Liu, H., Pan, Y., Jin, S., Sun, X., Jiang, Y., Wang, Y., ... & Xu, S. (2021). Associations between six common per-and polyfluoroalkyl substances and estrogens in neonates of China. Journal of hazardous materials, 407, 124378.",0.031,-0.014,0.076,NA,NA,64.6,NA,NA
LR,,completed (primary studies not provided),female,li_2024,ma_091,ma_m_448,tab2,,,PFAS,one,PFNA,yes,yes,E2 (estradiol),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",6,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Hence, we utilized multiple linear regressions to calculate the regression coefficient (?) and 95% confidence interval (CI) between each pair of PFAS and estrogen, adjusting for potential confounders (detailed information below)."" From Liu, H., Pan, Y., Jin, S., Sun, X., Jiang, Y., Wang, Y., ... & Xu, S. (2021). Associations between six common per-and polyfluoroalkyl substances and estrogens in neonates of China. Journal of hazardous materials, 407, 124378.",0.024,-0.035,0.083,NA,NA,74,NA,NA
LR,,need to extract primary studies (fig2),female,li_2024,ma_091,ma_m_449,tab2,,,PFAS,one,PFHxS,yes,yes,E2 (estradiol),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",6,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Hence, we utilized multiple linear regressions to calculate the regression coefficient (?) and 95% confidence interval (CI) between each pair of PFAS and estrogen, adjusting for potential confounders (detailed information below)."" From Liu, H., Pan, Y., Jin, S., Sun, X., Jiang, Y., Wang, Y., ... & Xu, S. (2021). Associations between six common per-and polyfluoroalkyl substances and estrogens in neonates of China. Journal of hazardous materials, 407, 124378.",0.03,0.013,0.046,NA,NA,0,NA,NA
LR,,completed (primary studies not provided),male,li_2024,ma_091,ma_m_450,tab4,,,PFAS,one,PFOA,yes,yes,E2 (estradiol),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",6,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Hence, we utilized multiple linear regressions to calculate the regression coefficient (?) and 95% confidence interval (CI) between each pair of PFAS and estrogen, adjusting for potential confounders (detailed information below)."" From Liu, H., Pan, Y., Jin, S., Sun, X., Jiang, Y., Wang, Y., ... & Xu, S. (2021). Associations between six common per-and polyfluoroalkyl substances and estrogens in neonates of China. Journal of hazardous materials, 407, 124378.",0.011,-0.019,0.04,NA,NA,78.9,NA,NA
LR,,need to extract primary studies (fig3),male,li_2024,ma_091,ma_m_451,tab4,,,PFAS,one,PFOA,yes,yes,TT (testosterone),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",7,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Estimated coefficient (?) with 95% CI of natural log-transformed testosterone (nmol/L) per each 1 (ng/mL) increase in PFAS levels in multivariate linear regression models."" From Zhou, Y., Hu, L. W., Qian, Z. M., Chang, J. J., King, C., Paul, G., ... & Do",-0.012,-0.023,-0.002,NA,NA,29.9,NA,NA
LR,,completed (primary studies not provided),male,li_2024,ma_091,ma_m_452,tab4,,,PFAS,one,PFOS,yes,yes,E2 (estradiol),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",6,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Hence, we utilized multiple linear regressions to calculate the regression coefficient (?) and 95% confidence interval (CI) between each pair of PFAS and estrogen, adjusting for potential confounders (detailed information below)."" From Liu, H., Pan, Y., Jin, S., Sun, X., Jiang, Y., Wang, Y., ... & Xu, S. (2021). Associations between six common per-and polyfluoroalkyl substances and estrogens in neonates of China. Journal of hazardous materials, 407, 124378.",-0.009,-0.024,0.006,NA,NA,82,NA,NA
LR,,need to extract primary studies (fig4),male,li_2024,ma_091,ma_m_453,tab4,,,PFAS,one,PFOS,yes,yes,TT (testosterone),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",7,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Estimated coefficient (?) with 95% CI of natural log-transformed testosterone (nmol/L) per each 1 (ng/mL) increase in PFAS levels in multivariate linear regression models."" From Zhou, Y., Hu, L. W., Qian, Z. M., Chang, J. J., King, C., Paul, G., ... & Do",-0.011,-0.021,0,NA,NA,56.4,NA,NA
LR,,completed (primary studies not provided),male,li_2024,ma_091,ma_m_454,tab4,,,PFAS,one,PFNA,yes,yes,TT (testosterone),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",7,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Estimated coefficient (?) with 95% CI of natural log-transformed testosterone (nmol/L) per each 1 (ng/mL) increase in PFAS levels in multivariate linear regression models."" From Zhou, Y., Hu, L. W., Qian, Z. M., Chang, J. J., King, C., Paul, G., ... & Do",-0.019,-0.053,0.014,NA,NA,66,NA,NA
LR,,completed (primary studies not provided),male,li_2024,ma_091,ma_m_455,tab4,,,PFAS,one,PFHxS,yes,yes,TT (testosterone),5A81.Z,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Testicular dysfunction or testosterone-related disorders, unspecified",6,,random and fixed effects model,NA,not reported,? (regression coefficient) value,linear,"""Estimated coefficient (?) with 95% CI of natural log-transformed testosterone (nmol/L) per each 1 (ng/mL) increase in PFAS levels in multivariate linear regression models."" From Zhou, Y., Hu, L. W., Qian, Z. M., Chang, J. J., King, C., Paul, G., ... & Do",-0.007,-0.027,0.013,NA,NA,20.4,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_456,fig1,,,PFAS,one,PFOS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,21,21,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.4,1.17,1.69,NA,NA,64.6,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_457,fig1,,,PFAS,one,PFOA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,21,21,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.1,0.92,1.31,NA,NA,64.5,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_458,fig1,,,PFAS,one,PFNA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,13,13,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.12,0.96,1.31,NA,NA,36.6,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_459,fig1,,,PFAS,one,PFHxS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,10,10,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.9,0.77,1.06,NA,NA,21.9,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_460,fig1,,,PFAS,one,PFDA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,9,9,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.08,0.94,1.24,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_461,fig1,,,PFAS,one,PFDoDA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.94,0.59,1.52,NA,NA,67.5,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_462,fig1,,,PFAS,one,PFHpS,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.01,0.64,1.62,NA,NA,36.6,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_463,fig1,,,PFAS,one,PFHpA,yes,no,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.77,1.48,NA,NA,67,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_464,fig2,,,PFAS,one,PFOS,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,13,13,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.2,1,1.44,NA,NA,60.6,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_465,fig2,,,PFAS,one,PFOA,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,14,14,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.03,1.01,1.06,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_466,fig2,,,PFAS,one,PFNA,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,9,9,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.14,0.95,1.35,NA,NA,44,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_467,fig2,,,PFAS,one,PFHxS,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,6,6,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.13,0.9,1.43,NA,NA,25.7,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_468,fig2,,,PFAS,one,PFDA,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.02,0.95,1.1,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_469,fig2,,,PFAS,one,PFUnDA,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.36,1.08,1.7,NA,NA,19.5,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_470,fig2,,,PFAS,one,PFHpA,yes,no,small for gestational age (SGA),KA20.0Z,"Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery",Certain conditions originating in the perinatal period,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1,0.9,1.1,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_471,fig2,,,PFAS,one,PFOS,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",NA,9,9,random effects model,NA,not reported,OR (odds ratio),NA,NA,1,0.89,1.13,NA,NA,34.1,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_472,fig3,,,PFAS,one,PFOA,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",NA,9,9,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.07,0.94,1.21,NA,NA,43.7,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_473,fig3,,,PFAS,one,PFHxS,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",NA,5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.03,0.96,1.11,NA,NA,0,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_474,fig3,,,PFAS,one,PFNA,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",NA,4,4,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.45,0.73,2.91,NA,NA,31.5,NA,NA
LR,,need to extract primary studies,NA,liu_2024,ma_092,ma_m_475,fig3,,,PFAS,one,PFDA,yes,no,miscarriage,JA00.08,Abortive outcome of pregnancy,"Pregnancy, childbirth or the puerperium",NA,5,5,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.59,0.95,2.67,NA,NA,62.8,NA,NA
,,,,liu_2024,ma_092,ma_m_476,fig4,,,PAEs,one,MEP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_477,fig4,,,PAEs,one,MBP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_478,fig4,,,PAEs,one,MEHP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_479,fig4,,,PAEs,one,MEHHP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_480,fig4,,,PAEs,one,MEOHP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_481,fig4,,,PAEs,one,MBzP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_482,fig4,,,PAEs,one,MCPP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_483,fig4,,,PAEs,one,MECPP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_484,fig4,,,PAEs,one,MiBP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_485,fig4,,,PAEs,one,MCNP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_486,fig4,,,PAEs,one,MCOP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
,,,,liu_2024,ma_092,ma_m_487,fig4,,,PAEs,one,DEHP,yes,,preterm birth (PTB),,pregnancy,,,,,,,,,,,,,,,,,,
LR,,need to extract primary studies (fig1),point estimates are expressed in grams,wright_2023,ma_093,ma_m_488,fig1,,,PFAS,one,PFNA,yes,yes,birth weight,KA21.2Z,Disorders of newborn related to length of gestation or fetal growth,Certain conditions originating in the perinatal period,NA,27,27,random effects model,NA,inverse variance,? (regression coefficient) value,linear,"""Multivariable linear regression models revealed the inverse associations of several long-chain PFASs with birth weight and ponderal index as well as the significant associations of perfluorobutanoic acid and perfluorooctanoic acid (PFOA) with IGFBP-3 levels. "" From Luo, D., Wu, W., Pan, Y., Du, B., Shen, M., & Zeng, L. (2021). Associations of prenatal exposure to per-and polyfluoroalkyl substances with the neonatal birth size and hormones in the growth hormone/insulin-like growth factor axis. Environmental Science & Technology, 55(17), 11859-11873.",-32.9,-47,-18.7,NA,NA,35.9,NA,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_489,fig2A,,,OCP,one,alpha-HCH,yes,,protein carbonyls (PC),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,0.035,0.017,0.054,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_490,fig2A,,,OCP,one,beta-HCH,yes,,protein carbonyls (PC),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,0.204,-0.021,0.429,NA,NA,77,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_491,fig2A,,,OCP,one,gamma-HCH,yes,,protein carbonyls (PC),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,0.111,-0.112,0.335,NA,NA,63,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_492,fig2A,,,OCP,one,"p,p?-DDE
",yes,,protein carbonyls (PC),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,0.059,-0.004,0.122,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_493,fig2A,,,OCP,one,"p,p?-DDT",yes,,protein carbonyls (PC),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,0.109,-0.166,0.383,NA,NA,73,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_494,fig2B,,,OCP,one,alpha-HCH,yes,,malondialdehyde (MDA),,oxidative stress,,NA,6,6,random effects model,NA,not reported,? (regression coefficient) value,,,0.02,-0.012,0.041,NA,NA,42,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_495,fig2B,,,OCP,one,beta-HCH,yes,,malondialdehyde (MDA),,oxidative stress,,NA,6,6,random effects model,NA,not reported,? (regression coefficient) value,,,0.245,-0.011,0.501,NA,NA,95,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_496,fig2B,,,OCP,one,gamma-HCH,yes,,malondialdehyde (MDA),,oxidative stress,,NA,6,6,random effects model,NA,not reported,? (regression coefficient) value,,,0.185,-0.067,0.437,NA,NA,91,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_497,fig2B,,,OCP,one,"o,p'-DDE",yes,,malondialdehyde (MDA),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,0.088,-0.206,0.383,NA,NA,91,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_498,fig2B,,,OCP,one,"p,p?-DDE",yes,,malondialdehyde (MDA),,oxidative stress,,NA,6,6,random effects model,NA,not reported,? (regression coefficient) value,,,0.121,0.056,0.187,NA,NA,29,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_499,fig2B,,,OCP,one,"o,p'-DDT",yes,,malondialdehyde (MDA),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,0.028,-0.008,0.064,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_500,fig2B,,,OCP,one,"p,p?-DDT",yes,,malondialdehyde (MDA),,oxidative stress,,NA,5,5,random effects model,NA,not reported,? (regression coefficient) value,,,0.114,-0.005,0.233,NA,NA,67,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_501,fig2C,,,OCP,one,alpha-HCH,yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,5,5,random effects model,NA,not reported,? (regression coefficient) value,,,-0.068,-0.142,0.005,NA,NA,25,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_502,fig2C,,,OCP,one,beta-HCH,yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,5,5,random effects model,NA,not reported,? (regression coefficient) value,,,-0.195,-0.395,0.006,NA,NA,86,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_503,fig2C,,,OCP,one,gamma-HCH,yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,5,5,random effects model,NA,not reported,? (regression coefficient) value,,,-0.165,-0.314,-0.016,NA,NA,74,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_504,fig2C,,,OCP,one,"o,p'-DDE",yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.042,-0.079,-0.004,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_505,fig2C,,,OCP,one,"p,p?-DDE",yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,5,5,random effects model,NA,not reported,? (regression coefficient) value,,,-0.129,-0.278,0.019,NA,NA,79,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_506,fig2C,,,OCP,one,"o,p'-DDT",yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.146,-0.6,0.308,NA,NA,92,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_507,fig2C,,,OCP,one,"p,p?-DDT",yes,,total antioxidant capacity (TAC),,oxidative stress,,NA,5,5,random effects model,NA,not reported,? (regression coefficient) value,,,-0.111,-0.21,-0.012,NA,NA,57,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_508,fig2D,,,OCP,one,alpha-HCH,yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.106,-0.401,0.188,NA,NA,76,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_509,fig2D,,,OCP,one,beta-HCH,yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,-0.14,-0.361,0.081,NA,NA,66,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_510,fig2D,,,OCP,one,gamma-HCH,yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,4,4,random effects model,NA,not reported,? (regression coefficient) value,,,-0.13,-0.353,0.094,NA,NA,69,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_511,fig2D,,,OCP,one,"o,p'-DDE",yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.02,-0.219,0.179,NA,NA,49,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_512,fig2D,,,OCP,one,"p,p?-DDE",yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.155,-0.335,0.026,NA,NA,57,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_513,fig2D,,,OCP,one,"o,p'-DDT",yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.023,-0.054,0.007,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_514,fig2D,,,OCP,one,"p,p?-DDT",yes,,acetylcholinesterase (AChE),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.085,-0.315,0.144,NA,NA,67,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_515,fig2E,,,OCP,one,alpha-HCH,yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.028,-0.061,0.006,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_516,fig2E,,,OCP,one,beta-HCH,yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.198,-0.53,0.134,NA,NA,90,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_517,fig2E,,,OCP,one,gamma-HCH,yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.134,-0.388,0.121,NA,NA,73,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_518,fig2E,,,OCP,one,"o,p'-DDE",yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.027,-0.079,0.025,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_519,fig2E,,,OCP,one,"p,p?-DDE",yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.133,-0.414,0.148,NA,NA,84,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_520,fig2E,,,OCP,one,"o,p'-DDT",yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.011,-0.048,0.025,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,chen_2023,ma_094,ma_m_521,fig2E,,,OCP,one,"p,p?-DDT",yes,,paraoxonase-1 (PON-1),,oxidative stress,,NA,3,3,random effects model,NA,not reported,? (regression coefficient) value,,,-0.094,-0.321,0.0133,NA,NA,73,,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_522,fig2B,,,PFAS,one,PFOA,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",4,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",8.19,-2.66,19.04,NA,NA,80.7,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_523,fig2B,,,PFAS,one,PFOS,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",6,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",8.22,3.93,12.51,NA,NA,94.2,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_524,fig2B,,,PFAS,one,PFHxS,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",5,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",0.31,-0.35,0.97,NA,NA,74.8,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_525,fig2B,,,PFAS,one,PFNA,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",6,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",0.54,-0.24,1.32,NA,NA,75.8,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_526,fig2B,,,PFAS,one,PFDA,yes,yes,total cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",4,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",3.13,-2.11,8.37,NA,NA,87.5,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_527,fig3B,,,PFAS,one,PFOA,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",4,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",6.25,-2.54,15.04,NA,NA,78,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_528,fig3B,,,PFAS,one,PFOS,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",4,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",12.04,5.08,18.99,NA,NA,92.7,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_529,fig3B,,,PFAS,one,PFHxS,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",4,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",4.56,-1.88,11,NA,NA,75,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_530,fig3B,,,PFAS,one,PFNA,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",5,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",1.02,-0.08,2.13,NA,NA,38.8,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_531,fig3B,,,PFAS,one,PFDA,yes,yes,low-density lipoprotein cholesterol,5C8Z,Metabolic disorders,"Endocrine, nutritional or metabolic diseases","Unspecified disorders of lipoprotein metabolism or lipidaemias. From the article: ""PFOA and PFOS were significantly associated with TC and LDL-C levels in adults. Whether these findings may translate into an elevated cardiovascular disease risk associated with PFAS exposure warrants further investigation.""",4,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",2.2,-1.37,5.77,NA,NA,79.5,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_532,fig4B,,,PFAS,one,PFOA,yes,no,higher homeostasis model assessment of insulin resistance (HOMA-IR),5A44,Other disorders of glucose regulation or pancreatic internal secretion,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,6,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",-0.227,-0.485,0.03,NA,NA,66.2,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_533,fig4B,,,PFAS,one,PFOS,yes,no,higher homeostasis model assessment of insulin resistance (HOMA-IR),5A44,Other disorders of glucose regulation or pancreatic internal secretion,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,6,6,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",-0.165,-0.292,-0.038,NA,NA,45.4,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_534,fig4B,,,PFAS,one,PFHxS,yes,no,higher homeostasis model assessment of insulin resistance (HOMA-IR),5A44,Other disorders of glucose regulation or pancreatic internal secretion,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,5,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",-0.126,-0.366,0.114,NA,NA,7.5,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_535,fig4B,,,PFAS,one,PFNA,yes,no,higher homeostasis model assessment of insulin resistance (HOMA-IR),5A44,Other disorders of glucose regulation or pancreatic internal secretion,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,5,5,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",-0.085,-0.182,0.013,NA,NA,9.9,NA,NA
LR,,need to extract primary studies (fig1),It also provides subcategories analysis that were not here extracted,zheng_2024,ma_095,ma_m_536,fig4B,,,PFAS,one,PFDA,yes,no,higher homeostasis model assessment of insulin resistance (HOMA-IR),5A44,Other disorders of glucose regulation or pancreatic internal secretion,"Endocrine, nutritional or metabolic diseases",Insulin-resistance syndromes,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We examined associations of prenatal and mid-childhood PFAS plasma concentrations with lipids and ALT in mid-childhood using multivariable linear regression models."" From Mora, A. M., Fleisch, A. F., Rifas-Shiman, S. L., Baidal, J. A. W., Pardo, L., Webster, T. F., ... & Sagiv, S. K. (2018). Early life exposure to per-and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environment international, 111, 1-13.",-0.642,-1.324,0.039,NA,NA,79,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2A.,seyyedsalehi_2023,ma_096,ma_m_537,tab1,,,PFAS,one,PFOA,yes,no,kidney cancer,2C90,"Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues",Neoplasms,"Malignant neoplasms of kidney, except renal pelvis",,6,random effects model,NA,not reported,RR (risk ratio),NA,NA,1.23,0.99,1.51,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2A.,seyyedsalehi_2023,ma_096,ma_m_538,tab1,,,PFAS,multiple,NA,yes,no,kidney cancer,2C90,"Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues",Neoplasms,"Malignant neoplasms of kidney, except renal pelvis",,4,random effects model,NA,not reported,RR (risk ratio),NA,NA,1.12,0.95,1.31,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2B.,seyyedsalehi_2023,ma_096,ma_m_539,tab1,,,PFAS,one,PFOA,yes,no,liver cancer,2C12.0,"Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues",Neoplasms,Malignant neoplasm of liver,,8,random effects model,NA,not reported,RR (risk ratio),NA,NA,1.05,0.93,1.18,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2B.,seyyedsalehi_2023,ma_096,ma_m_540,tab1,,,PFAS,one,PFOS,yes,no,liver cancer,2C12.0,"Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues",Neoplasms,Malignant neoplasm of liver,,4,random effects model,NA,not reported,RR (risk ratio),NA,NA,1.86,0.81,4.25,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2B.,seyyedsalehi_2023,ma_096,ma_m_541,tab1,,,PFAS,multiple,NA,yes,no,liver cancer,2C12.0,"Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues",Neoplasms,Malignant neoplasm of liver,,4,random effects model,NA,not reported,RR (risk ratio),NA,NA,0.91,0.82,1.02,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2C.,seyyedsalehi_2023,ma_096,ma_m_542,tab1,,,PFAS,one,PFOA,yes,no,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,NA,,5,random effects model,NA,not reported,RR (risk ratio),NA,NA,1.28,0.99,1.64,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),estimate comes from tab1. Primary study level estimates can be extracted from fig2C.,seyyedsalehi_2023,ma_096,ma_m_543,tab1,,,PFAS,multiple,NA,yes,no,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,NA,,3,random effects model,NA,not reported,RR (risk ratio),NA,NA,1.01,0.7,1.46,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),subcategory prenatal and postnatal exposure also provided,frangione_2023,ma_097,ma_m_544,fig2,,,PFAS,one,PFOS,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",pediatric,12,17,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,-0.005,-0.02,0.01,NA,NA,74.68,NA,NA
LR,,need to extract primary studies (fig1),NA,frangione_2023,ma_097,ma_m_545,fig2,,,PFAS,one,PFOS,yes,yes,waist circumference z-score,?,body metrics,"Endocrine, nutritional or metabolic diseases",NA,3,6,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,-0.001,-0.01,0.004,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),subcategory prenatal and postnatal also provided,frangione_2023,ma_097,ma_m_546,fig3,,,PFAS,one,PFOA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",NA,,20,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,-0.003,-0.02,0.01,NA,NA,58.01,NA,NA
LR,,need to extract primary studies (fig1),NA,frangione_2023,ma_097,ma_m_547,fig3,,,PFAS,one,PFOA,yes,yes,waist circumference z-score,?,body metrics,"Endocrine, nutritional or metabolic diseases",NA,,7,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,-0.02,-0.05,0.02,NA,NA,65.94,NA,NA
LR,,need to extract primary studies (fig1),subcategory prenatal and postnatal also provided,frangione_2023,ma_097,ma_m_548,fig4,,,PFAS,one,PFHxS,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",NA,,9,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,-0.03,-0.05,-0.001,NA,NA,34.38,NA,NA
LR,,need to extract primary studies (fig1),NA,frangione_2023,ma_097,ma_m_549,fig4,,,PFAS,one,PFHxS,yes,yes,waist circumference z-score,?,body metrics,"Endocrine, nutritional or metabolic diseases",NA,2,4,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,-0.001,-0.03,0.03,NA,NA,56.11,NA,NA
LR,,need to extract primary studies (fig1),subcategory prenatal and postnatal also provided,frangione_2023,ma_097,ma_m_550,fig5,,,PFAS,one,PFNA,yes,yes,body mass index (BMI) z-score,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",NA,5,7,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,0.01,-0.02,0.03,NA,NA,29.31,NA,NA
LR,,need to extract primary studies (fig1),NA,frangione_2023,ma_097,ma_m_551,fig5,,,PFAS,one,PFNA,yes,yes,waist circumference z-score,?,body metrics,"Endocrine, nutritional or metabolic diseases",NA,2,4,random effects model,NA,not reported,change per unit increase in log10-transformed PFAS concentration,NA,NA,0.01,-0.01,0.03,NA,NA,21.78,NA,NA
LR,,need to extract primary studies (fig1),women,mahdavi_2023,ma_098,ma_m_552,fig2,,,PFAS,one,PFOA,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.005,-0.02,0.01,NA,NA,19.2,NA,NA
LR,,need to extract primary studies (fig1),men,mahdavi_2023,ma_098,ma_m_553,fig2,,,PFAS,one,PFOA,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.004,-0.02,0.01,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),women,mahdavi_2023,ma_098,ma_m_554,fig3,,,PFAS,one,PFOS,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.01,-0.02,-0.004,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),men,mahdavi_2023,ma_098,ma_m_555,fig3,,,PFAS,one,PFOS,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",0,-0.01,0.01,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig3),NA,maradpour_2021,ma_099,ma_m_556,fig3,,,OPEs,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,1,2,fixed effects model,NA,not reported,OR (crude),,,1.12,0.75,1.68,NA,NA,0,,NA
LR,,need to extract primary studies (fig3),NA,maradpour_2021,ma_099,ma_m_557,fig3,,,OCP,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,2,14,fixed effects model,NA,not reported,OR (crude),,,1.32,1.14,1.53,NA,NA,0,,NA
LR,,completed (primary studies not provided),NA,maradpour_2021,ma_099,ma_m_558,table 3,,,OPEs,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,NA,NA,fixed effects model,NA,not reported,OR (adjusted),,,1.06,1,1.12,NA,NA,51.4,,NA
LR,,completed (primary studies not provided),NA,maradpour_2021,ma_099,ma_m_559,table 3,,,carbamates,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,NA,NA,fixed effects model,NA,not reported,OR (adjusted),,,1.52,1.04,2.23,NA,NA,NA,,NA
LR,,completed (primary studies not provided),NA,maradpour_2021,ma_099,ma_m_560,table 3,,,OCP,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,NA,NA,fixed effects model,NA,not reported,OR (adjusted),,,1.16,0.99,1.36,NA,NA,43.3,,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_561,fig2,,,PFAS,one,PFOA,yes,yes,bone mineral density (BMD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",proxy of osteoporosis,4,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.02,-0.04,0.01,NA,NA,90.3,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_562,fig2,,,PFAS,one,PFOS,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,4,4,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.01,-0.03,0,NA,NA,75.7,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_563,fig2,,,PFAS,one,PFHxS,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",0,-0.01,0.01,NA,NA,74.6,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_564,fig2,,,PFAS,one,PFNA,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.01,-0.03,0.02,NA,NA,60.6,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_565,fig3,,,PFAS,one,PFOA,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.11,-0.17,-0.04,NA,NA,5.7,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_566,fig3,,,PFAS,one,PFOS,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.05,-0.09,0,NA,NA,14,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_567,fig3,,,PFAS,one,PFHxS,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",-0.02,-0.05,0.01,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_568,fig3,,,PFAS,one,PFNA,yes,yes,bone mineral density (BMD),FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,proxy of osteoporosis,3,3,random effects model,NA,not reported,? (regression coefficient) value,linear,"""We constructed full multivariable linear regression models with TFBMD, FNBMD, and LSBMD as dependent variables and individual PFAS concentrations as ln-transformed continuous predictors or in quartiles while adjusting for covariates related to BMD that have been described previously in the literature"" From Khalil, N., Chen, A., Lee, M., Czerwinski, S. A., Ebert, J. R., DeWitt, J. C., & Kannan, K. (2016). Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the US population in NHANES 2009–2010. Environmental health perspectives, 124(1), 81-87.",0,-0.05,0.05,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_569,fig4,,,PFAS,one,PFOA,yes,no,osteoporosis,FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.22,0.98,1.52,NA,NA,56,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_570,fig4,,,PFAS,one,PFOS,yes,no,osteoporosis,FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,0.97,0.79,1.2,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_571,fig4,,,PFAS,one,PFHxS,yes,no,osteoporosis,FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.37,1.12,1.68,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,khosrojerdi_2024,ma_100,ma_m_572,fig4,,,PFAS,one,PFNA,yes,no,osteoporosis,FB83.1Z,Osteopathies or chondropathies,Diseases of the musculoskeletal system or connective tissue,NA,3,3,random effects model,NA,not reported,OR (odds ratio),NA,NA,1.13,0.92,1.4,NA,NA,48.9,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk,chang_2024,ma_101,ma_m_573,fig3A,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",9,9,random effects model,NA,not reported,relative risk,NA,NA,0.95,0.77,1.18,NA,NA,67,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk,chang_2024,ma_101,ma_m_574,fig3B,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",9,9,random effects model,NA,not reported,relative risk,NA,NA,0.98,0.87,1.11,NA,NA,54,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk,chang_2024,ma_101,ma_m_575,fig3C,,,PFAS,one,PFHxS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",7,7,random effects model,NA,not reported,relative risk,NA,NA,0.91,0.75,1.09,NA,NA,76,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk,chang_2024,ma_101,ma_m_576,fig3D,,,PFAS,one,PFNA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",7,7,random effects model,NA,not reported,relative risk,NA,NA,0.86,0.66,1.12,NA,NA,83,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by estrogen receptor (ER-),chang_2024,ma_101,ma_m_577,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",5,5,random effects model,NA,not reported,relative risk,NA,NA,0.92,0.59,1.44,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by estrogen receptor (ER+),chang_2024,ma_101,ma_m_578,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",5,5,random effects model,NA,not reported,relative risk,NA,NA,0.85,0.66,1.1,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal estrogen receptor (ER-),chang_2024,ma_101,ma_m_579,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",3,3,random effects model,NA,not reported,relative risk,NA,NA,1.55,0.9,2.67,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal estrogen receptor (ER+),chang_2024,ma_101,ma_m_580,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",3,3,random effects model,NA,not reported,relative risk,NA,NA,0.97,0.67,1.39,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by progesterone receptor (PR-),chang_2024,ma_101,ma_m_581,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",4,4,random effects model,NA,not reported,relative risk,NA,NA,0.99,0.64,1.54,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by progesterone receptor (PR+),chang_2024,ma_101,ma_m_582,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",4,4,random effects model,NA,not reported,relative risk,NA,NA,0.81,0.53,1.23,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal progesterone receptor (PR-),chang_2024,ma_101,ma_m_583,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",2,2,random effects model,NA,not reported,relative risk,NA,NA,1.41,0.91,2.18,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal progesterone receptor (PR+),chang_2024,ma_101,ma_m_584,fig4,,,PFAS,one,PFOA,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",2,2,random effects model,NA,not reported,relative risk,NA,NA,1.03,0.39,2.72,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by estrogen receptor (ER-),chang_2024,ma_101,ma_m_585,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",5,5,random effects model,NA,not reported,relative risk,NA,NA,0.72,0.54,0.95,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by estrogen receptor (ER+),chang_2024,ma_101,ma_m_586,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",5,5,random effects model,NA,not reported,relative risk,NA,NA,1.02,0.74,1.4,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal estrogen receptor (ER-),chang_2024,ma_101,ma_m_587,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",3,3,random effects model,NA,not reported,relative risk,NA,NA,0.9,0.56,1.42,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal estrogen receptor (ER+),chang_2024,ma_101,ma_m_588,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",3,3,random effects model,NA,not reported,relative risk,NA,NA,1.07,0.62,1.84,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by progesterone receptor (PR-),chang_2024,ma_101,ma_m_589,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",4,4,random effects model,NA,not reported,relative risk,NA,NA,0.74,0.57,0.97,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by progesterone receptor (PR+),chang_2024,ma_101,ma_m_590,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",4,4,random effects model,NA,not reported,relative risk,NA,NA,1.1,0.68,1.78,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal progesterone receptor (PR-),chang_2024,ma_101,ma_m_591,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",2,2,random effects model,NA,not reported,relative risk,NA,NA,0.86,0.6,1.24,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),relative risk for per-natural-log-unit increase in serum/plasma per- and polyfluoroalkyl substances (PFAS) concentrations (ng/mL) and breast cancer risk by postmenopausal progesterone receptor (PR+),chang_2024,ma_101,ma_m_592,fig5,,,PFAS,one,PFOS,yes,no,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",2,2,random effects model,NA,not reported,relative risk,NA,NA,1.55,1.06,2.26,NA,NA,NA,NA,NA
LR,,need to extract primary studies (fig1),NA,xu_2023,ma_102,ma_m_593,fig3,,,OPs,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,5,8,random effects model,NA,not reported,OR (odds ratio),,,1.14,1.04,1.24,NA,NA,18.3,,NA
LR,,need to extract primary studies (fig1),NA,xu_2023,ma_102,ma_m_594,fig3,,,OCP,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,3,3,random effects model,NA,not reported,OR (odds ratio),,,1.17,0.86,1.61,NA,NA,24.6,,NA
LR,,need to extract primary studies (fig1),NA,xu_2023,ma_102,ma_m_595,fig3,,,pyrethroid,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,2,2,random effects model,NA,not reported,OR (odds ratio),,,1.4,1.09,1.8,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),NA,xu_2023,ma_102,ma_m_596,fig3,,,carbamates,multiple,NA,yes,,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,3,3,random effects model,NA,not reported,OR (odds ratio),,,1.02,0.69,1.5,NA,NA,59.6,,NA
LR,,need to extract primary studies (fig1),NA,xu_2023,ma_102,ma_m_597,fig4,,,OPs,multiple,NA,yes,,attention deficit hyperactivity disorder (ADHD),,neurological,,NA,5,6,fixed effects model,NA,not reported,OR (odds ratio),,,1.15,0.9,1.47,NA,NA,53.8,,NA
LR,,need to extract primary studies (fig1),NA,xu_2023,ma_102,ma_m_598,fig4,,,OCP,multiple,NA,yes,,attention deficit hyperactivity disorder (ADHD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,3,4,fixed effects model,NA,not reported,OR (odds ratio),,,1.22,1.03,1.45,NA,NA,0,,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_599,tab2,,,PFAS,one,PFOA,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,5,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.98,0.94,1.02,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_600,tab2,,,PFAS,one,PFOS,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,5,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.97,0.92,1.03,NA,NA,22.1,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_601,tab2,,,PFAS,one,PFNA,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,3,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.88,0.75,1.04,NA,NA,49.9,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_602,tab2,,,PFAS,one,PFHxS,yes,no,attention deficit hyperactivity disorder (ADHD),6A05.Z,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,3,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.97,0.91,1.04,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_603,tab2,,,PFAS,one,PFOA,yes,no,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,5,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.99,0.89,1.09,NA,NA,42.1,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_604,tab2,,,PFAS,one,PFOS,yes,no,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,5,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.91,0.77,1.08,NA,NA,56,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_605,tab2,,,PFAS,one,PFNA,yes,no,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,4,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,0.89,0.7,1.13,NA,NA,51,NA,NA
LR,,need to extract primary studies (fig1),A random-effects model was used in cases when I2 ? 50. Primary study estimates can be extracted from fig2 and 3.,yao_2023,ma_103,ma_m_606,tab2,,,PFAS,one,PFHxS,yes,no,autismspectrum disorder (ASD),?,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,4,,random and fixed effects model,"""A random-effects model was used in cases when I2 ? 50%""",not reported,OR (odds ratio),NA,NA,1.02,0.88,1.2,NA,NA,61.3,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_607,tab1,,pregnant women,PFAS,one,PFOA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,11,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.45,1.07,1.94,NA,NA,53.8,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_608,tab1,,pregnant women,PFAS,one,PFOS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,12,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.11,0.94,1.31,NA,NA,3.1,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_609,tab1,,pregnant women,PFAS,one,PFHxS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,11,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.16,1,1.36,NA,NA,44.1,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_610,tab1,,pregnant women,PFAS,one,PFNA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,8,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.05,0.86,1.28,NA,NA,38.8,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_611,tab1,,pregnant women,PFAS,one,PFDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,6,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.02,0.83,1.26,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_612,tab1,,pregnant women,PFAS,one,PFBS,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,4,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.44,1.16,1.79,NA,NA,0.3,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_613,tab1,,pregnant women,PFAS,one,PFUnDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,3,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.84,0.66,1.08,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_614,tab1,,pregnant women,PFAS,one,PFDoDA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,2,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,3.7,0.33,40.84,NA,NA,96.7,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_615,tab1,,pregnant women,PFAS,one,PFHpA,yes,no,gestational diabetes mellitus,JA63.2,Certain specified maternal disorders predominantly related to pregnancy,"Pregnancy, childbirth or the puerperium",diabetes mellitus arising in pregnancy,2,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.41,1.1,1.82,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_616,tab2,,pregnant women,PFAS,one,PFOA,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.1,0.99,1.22,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_617,tab2,,pregnant women,PFAS,one,PFOS,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.15,0.88,1.49,NA,NA,66.5,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_618,tab2,,pregnant women,PFAS,one,PFHxS,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,5,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.86,0.67,1.11,NA,NA,70,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_619,tab2,,pregnant women,PFAS,one,PFNA,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.11,0.79,1.55,NA,NA,70.9,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_620,tab2,,pregnant women,PFAS,one,PFDA,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.01,0.86,1.2,NA,NA,13.8,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_621,tab2,,pregnant women,PFAS,one,PFBS,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.27,1.14,1.41,NA,NA,49.1,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_622,tab2,,pregnant women,PFAS,one,PFDoDA,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.83,0.68,1.02,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_623,tab2,,pregnant women,PFAS,one,PFHpA,yes,no,hypertensive disorders of pregnancy (HDP),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,2,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.88,0.66,1.16,NA,NA,67.3,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_624,tab3,,pregnant women,PFAS,one,PFOA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,7,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.09,1,1.19,NA,NA,26.9,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_625,tab3,,pregnant women,PFAS,one,PFOS,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.96,0.84,1.1,NA,NA,45.8,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_626,tab3,,pregnant women,PFAS,one,PFHxS,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.09,0.98,1.22,NA,NA,45.1,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_627,tab3,,pregnant women,PFAS,one,PFNA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.02,0.8,1.3,NA,NA,50.5,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_628,tab3,,pregnant women,PFAS,one,PFDA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,5,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.01,0.71,1.43,NA,NA,63.4,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_629,tab3,,pregnant women,PFAS,one,PFBS,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,2,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.18,0.87,1.6,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_630,tab3,,pregnant women,PFAS,one,PFDoDA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.71,0.57,0.87,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_631,tab3,,pregnant women,PFAS,one,PFHpA,yes,no,gestational hypertension,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.43,1.15,1.78,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_632,tab4,,pregnant women,PFAS,one,PFOA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.14,0.95,1.38,NA,NA,7.4,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_633,tab4,,pregnant women,PFAS,one,PFOS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,9,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.01,0.97,1.04,NA,NA,9.3,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_634,tab4,,pregnant women,PFAS,one,PFHxS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,9,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.96,0.75,1.24,NA,NA,64.3,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_635,tab4,,pregnant women,PFAS,one,PFNA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,7,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.04,0.94,1.14,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_636,tab4,,pregnant women,PFAS,one,PFDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1,0.97,1.02,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_637,tab4,,pregnant women,PFAS,one,PFBS,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,2,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,1.23,0.73,2.08,NA,NA,64.9,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_638,tab4,,pregnant women,PFAS,one,PFUnDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.87,0.62,1.22,NA,NA,83,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_639,tab4,,pregnant women,PFAS,one,PFDoDA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.86,0.65,1.13,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,pang_2024,ma_104,ma_m_640,tab4,,pregnant women,PFAS,one,PFHpA,yes,no,preeclampsia,JA24.Z,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""The I 2 )/ statistical test and Cochran Q were utilized to quantify heterogeneity’s impact. Random effect models were appropriate to apply if studies showed significant heterogeneity (P < 0.05 or I 2 ? 50%). Alternatively, fixed effect models were chosen (Bowden et al., 2011).""",not reported,OR (odds ratio),NA,NA,0.99,0.94,1.03,NA,NA,38.9,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_641,fig1a,,pregnant women,PFAS,one,PFOS,yes,yes,thyroid stimulating hormone (TSH),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,13,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.01,0.009,0.011,NA,NA,26,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_642,fig1a,,pregnant women,PFAS,one,PFOA,yes,yes,thyroid stimulating hormone (TSH),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,13,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.01,0.009,0.011,NA,NA,0,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_643,fig1a,,pregnant women,PFAS,one,PFHxS,yes,yes,thyroid stimulating hormone (TSH),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,12,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.006,-0.003,0.014,NA,NA,95.8,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_644,fig1a,,pregnant women,PFAS,one,PFNA,yes,yes,thyroid stimulating hormone (TSH),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,13,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.01,-0.018,0.036,NA,NA,54.6,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_645,fig1a,,pregnant women,PFAS,one,PFDA,yes,yes,thyroid stimulating hormone (TSH),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.01,0.009,0.01,NA,NA,30.7,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_646,fig1b,,pregnant women,PFAS,one,PFOS,yes,yes,triiodothyronine (TT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,7,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.008,-0.004,0.019,NA,NA,59.4,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_647,fig1b,,pregnant women,PFAS,one,PFOA,yes,yes,triiodothyronine (TT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,7,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.001,-0.007,0.009,NA,NA,57,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_648,fig1b,,pregnant women,PFAS,one,PFHxS,yes,yes,triiodothyronine (TT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,6,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,-0.002,-0.005,0.001,NA,NA,29.2,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_649,fig1b,,pregnant women,PFAS,one,PFNA,yes,yes,triiodothyronine (TT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,7,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,-0.004,-0.02,0.013,NA,NA,57.9,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_650,fig1b,,pregnant women,PFAS,one,PFDA,yes,yes,triiodothyronine (TT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.034,-0.023,0.092,NA,NA,80.5,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_651,fig1c,,pregnant women,PFAS,one,PFOS,yes,yes,thyroxin (TT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.038,-0.009,0.036,NA,NA,72.7,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_652,fig1c,,pregnant women,PFAS,one,PFOA,yes,yes,thyroxin (TT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,9,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.007,-0.007,0.02,NA,NA,1.6,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_653,fig1c,,pregnant women,PFAS,one,PFHxS,yes,yes,thyroxin (TT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.001,-0.013,0.014,NA,NA,22.1,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_654,fig1c,,pregnant women,PFAS,one,PFNA,yes,yes,thyroxin (TT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,9,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,-0.02,-0.066,0.025,NA,NA,63.7,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_655,fig1c,,pregnant women,PFAS,one,PFDA,yes,yes,thyroxin (TT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.023,-0.289,0.335,NA,NA,61.3,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_656,fig1d,,pregnant women,PFAS,one,PFOS,yes,yes,free T3 (FT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.031,-0.009,0.072,NA,NA,69.7,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_657,fig1d,,pregnant women,PFAS,one,PFOA,yes,yes,free T3 (FT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.011,-0.019,0.041,NA,NA,65.6,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_658,fig1d,,pregnant women,PFAS,one,PFHxS,yes,yes,free T3 (FT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.02,-0.018,0.059,NA,NA,64.6,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_659,fig1d,,pregnant women,PFAS,one,PFNA,yes,yes,free T3 (FT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.002,-0.015,0.02,NA,NA,58.7,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_660,fig1d,,pregnant women,PFAS,one,PFDA,yes,yes,free T3 (FT3),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,3,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.05,-0.021,0.122,NA,NA,75.1,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_661,fig1e,,pregnant women,PFAS,one,PFOS,yes,yes,free T4 (FT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,10,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.005,-0.001,0.012,NA,NA,82.2,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_662,fig1e,,pregnant women,PFAS,one,PFOA,yes,yes,free T4 (FT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,10,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,-0.001,-0.012,0.01,NA,NA,72.3,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_663,fig1e,,pregnant women,PFAS,one,PFHxS,yes,yes,free T4 (FT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,8,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.001,-0.013,0.014,NA,NA,22.1,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_664,fig1e,,pregnant women,PFAS,one,PFNA,yes,yes,free T4 (FT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,10,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.001,-0.009,0.011,NA,NA,83.5,NA,NA
LR,,need to extract primary studies (fig1),NA,zhang_2023,ma_105,ma_m_665,fig1e,,pregnant women,PFAS,one,PFDA,yes,yes,free T4 (FT4),,"Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium","Pregnancy, childbirth or the puerperium",NA,4,,random and fixed effects model,"""the fixed-effects model was used for merging when there was no heterogeneity among the included literature (I 2 <50% and P > 0.1), and otherwise the random-effects model was chosen (Cumpston et al., 2019).""",not reported,? (regression coefficient) value,linear,“We used ?-value to represent the joint association between exposure to PFAS during pregnancy and maternal or fetal thyroid function.”,0.001,-0.014,0.015,NA,NA,0,NA,NA
